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ABSTRACT
Mesenchymal  stem  cells  (MSCs),  are  plastic  adherent  cells  that  are  readily
isolated  from  various  sources,  possess  stem-cell-like  properties  and  show  unique
beneficial features in in vivo models of diseases.
In present dissertation we investigated the aspects of MSCs biology related to
both in vitro properties and in vivo abilities to benefit in diseases.
The in vitro part of the dissertation addresses the question of heterogeneity in
single-cell derived cultures of human MSCs. Laser capture microdissection was used to
isolate distinct inside and outside regions of the colony for RNA isolation. When assayed
by microarray the cells from inside and outside regions of the colony showed distinct
patterns of gene expression profile. In functional studies, however, we did not find any
differences – the cells perform similarly in cloning and in vitro growth assays.
In the in vivo part of the dissertation we investigated the effects of human MSCs
and their  secreted protein tumor-necrosis factor stimulated gene/protein 6 (TSG-6) in
two models of lung injury - hydrocloric-acid (HCl)-induced lung injury and bleomycin-
induced  lung  injury  in  mice.  We  showed  that  intraperitoneal  administration  (IP)  of
human MSCs improved lung function and inhibited inflammation in the lungs after HCl
lung injury.  Human recombinant TSG-6 inhibited inflammation in both, HCl-induced
lung injury and bleomycin-induced lung injury, however it improved lung function only
in mice injured with bleomycin.
Finally we investigated the effects of MSCs administered inside the peritoneal
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cavity to  explain  the  beneficial  effects  in  HCl-induced lung injury.  We showed that
MSCs aggregated rapidly after the injection IP and preconditioned immune system by
recruiting immune cells to peritoneal cavity and by triggering the production of various
classes of cytokines. We utilized real-time polymerase chain reaction (PCR) and in vivo
imaging to estimate the amount MSCs present in various organs of peritoneal cavity.
Most of MSCs were found in omentum and mesenteric tissues, only negligible amount
of cells was recovered from lymph nodes and spleen.
In conclusion, the dissertation is expanding the existing knowledge about MSCs,
increases our knowledge both in understanding the basic biology of the cells and their
interaction with the host organism.
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NOMENCLATURE
ALI Acute Lung Injury
ARDS Acute Respiratory Distress Syndrome
BALB/c Bagg Albino (inbred research mouse strain)
BMP Bone Morphogenetic Protein
CCM Complete Culture Medium
CCR CC chemokine receptor
CD Cluster Of Differentiation
cDNA Complementary Deoxyribonucleic Acid
CFU-F Colony Forming Unit - Fibroblast
COX2 cyclooxygenase 2
CXCL CXC chemokine ligand
CXCR CXC chemokine receptor
DAPI 4',6-diamidino-2-phenylindole
DKK Dickkopf homolog
DNA Deoxyribonucleic Acid
ECM Extracellular Matrix
EDTA Ethylenediaminetetraacetic Acid
EGF Epidermal Growth Factor
ELISA Enzyme-Linked Immuno Assay
Fgf Fibroblast Growth Factor
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GAPDH Glyceraldehyde 3-Phosphate Dehydrogenase
GFP Green Fluorescent Protein
GVHD Graft-Versus-Host Disease
HCl Hydrochloric Acid
HLA Human Leukocyte Antigen
HSC Hematopoietic Stem Cell
IDO Indoleamine-2,3-dioxygenase
IGF Insulin-Like Growth Factor
IN Inner Region Of A Colony
iNOS Nitric Oxide Synthase
IFN Interferon
ISCT International Society For Cell Therapy
ITGA Integrin α
IP Intraperitoneal
IV Intravenous
IT Intratracheal
JLN Jejunal Lymph Nodes
kDa Kilodalton
LPS Lypopolysaccharide
MCP1 Monocyte Chemoattractant Protein-1
MHC Major Histocompatibility Complex
MLR Mixed Lymphocyte Reaction
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MSCs Mesenchymal Stem Cells
mRNA Messenger Ribonucleic Acid
MT Mesentery
NaCl Sodium chloride
NCBI National Center for Biotechnology Information
NIH National Institutes of Health
NO Nitric Oxide
OI Osteogenesis Imperfecta
OM Omentum
OUT Outer Region of a Colony
PCR Polymerase Chain Reaction
PFA Paraformaldehyde
pH Potency of Hydrogen
PGE2 Prostaglandin E2
PLP Peritoneal Lavage Pellet
PODXL Podocalyxin-Like
RFU Relative Fluorescence Units
RLU Relative Luminescence Units
ROS Reactive Oxygen Species
RS Rapidly Self-Renewing
RT Reverse Transcriptase
SD Standard Deviation
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SDF Stromal Cell-Derived Factor
SEM Standard Error of Mean
SOX Sex Determining Region Y-Box
SP Spleen
SR Slowly Replicating
STC-1 Stanniocalcin-1
SYNPO Synaptopodin
TNF-α Tumor Necrosis Factor alpha
TGF Transforming Growth Factor
THBS Thrombospondin
Treg T-Regulatory Cell
Th1/Th2 T-helper Cell Type 1 or 2
UV Ultra-Violet
VEGF Vascular Endothelial Growth Factor
VCAM Vascular Cell Adhesion Molecule
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CHAPTER I
INTRODUCTION
I.1 Mesenchymal Stem Cells – Introduction
Human mesenchymal stem cells, or MSCs, have been occupying the minds of
many brilliant scientists for more than half a century. These cells, commonly isolated
from bone marrow, fat and other tissues, were originally discovered by Soviet biologist
Aleksandr Friedenstein [1] in preparations of bone marrow from rabbits, allegedly, while
trying to find a remedy to cure the effects of nuclear weapon attack. Thus Friedenstein
and his colleagues discovered that plastic-adherent fraction of bone marrow is capable of
forming bone once placed in peritoneal cavities [1].
Since then the research on MSCs has exploded in geometric progression.  The
metrics behind it are impressive: MSCs are being studied by numerous teams across the
globe, that produce on average 100 publications each week  [2]. In 2014-2015 the US
National Institutes of Health spent more than $170,000,000 funding projects directly or
indirectly involving MSCs  [3].  Clinicaltrials.gov reports  439 trials  with MSCs being
carried out virtually on every continent, with China (147), European Union (104) and
United States (71) in the lead [4].
The popularity of MSCs is based on several properties of these cells. First, the
stem-  and  progenitor-cells-like  properties.  MSCs  have  been  repeatedly  shown  to
differentiate  into  various  types  of  cells  including bone  [5]–[8],  fat  [5],  [6],  [8],  [9],
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cartilage  [10]–[13] neurons  and  glial  cells  [14],  [15] and  others,  including  alveolar
epithelium cells, retinal and skin epithelial cells [16]–[24]. The ability of MSCs cells to
differentiate warranted the research in regenerative medicine, especially in diseases that
affect bone and cartilage. Secondly, MSCs showed promising results in various models
of diseases by modulating inflammation and immunity  [25]. Lastly, the practicality of
work with MSCs. The cells are relatively easy to obtain and maintain in culture and
basic  protocols  for  cells  isolation,  expansion and differentiation  are  freely available.
Moreover, to facilitate the research of these cells Texas A&M Health Science Center is
hosting  NIH-funded  MSCs  distribution  center  that  provides  characterized  MSCs  to
researchers worldwide [26]
The following sections of introduction will discuss these properties in more detail
and will provide rationale for the studies described in the main body of dissertation.
I.2 MSCs: characteristics and heterogeneity
As mentioned in previous section, MSCs were originally discovered as plastic-
adherent cells in bone marrow of rabbits by Friedenstein and colleagues in 1960s-1970s
[1], [27]. Surprisingly, the transplantation of these cells inside peritoneal cavity did not
result in generation of hematopoetic cells. Instead formation of heterotopic bone tissue
was  observed  [1].  The  discovered  plastic  adherent  cells  resembled  fibroblasts  in
appearance, grew rapidly in culture and were able to form single-cell-derived colonies
and were named colony-forming unit-fibroblast   [28].  The term “mesenchymal  stem
cells”  was first  used  in  1990's  to  underline  the  multipotentiality of  MSCs and their
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similarity  with  embryonic  stem cells  [29].  In  current  literature  MSCs  appear  under
various  names  –  multipotent  adult  stromal  cells,  bone  marrow  stromal  cells,
mesenchymal stem/progenitor  cells  and others.  In  2005 the  International  Society for
Cellular Therapy (ISCT) published a position paper defining minimal criteria for MSCs
[30].  It  covers  three  areas  –  in  vitro  culture  requirements  (plastic  adherence),
differentiation requirements (bone, cartilage and fat) and epitope marker requirements
(negative for hematopoetic markers CD45, CD34, CD14 or CD11b, CD79alpha, CD19
and HLA-DR) and positive for  CD105,  CD73,  CD90.  The ISCT definition is  being
actively used by researchers and was being cited more than 3400 times [2].
Clonogenicity of MSCs is an important quality of MSCs showing their potential
for self renewal [31]. Although the cells in colonies arise from a single progenitor, their
homogeneity  is  questionable.  When  MSCs  clones  were  subjected  to  differentiating
conditions  some  of  them  produced  only  cells  of  one  lineage  –  either  bone,  fat  or
cartilage, while others were able to produce cells of two or more origins [5], [31], [32]. It
has been suggested that the MSCs colony represents a quasi  in vitro niche  [33] where
different  regions  of  colony  vary  in  the  composition  of  produced  factors  that  play
important roles in maintenance of the undifferentiated state or, in contrast, promoting of
differentiation processes.
The heterogeneity of MSCs has been shown on other levels as well. Thus it was
shown that the culture of MSCs undergo changes in their gene expression profile  [34]
and antigen presentation [35]. Earlier passages of MSCs contain larger amount of cells
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that have high clonogenic ability [10] and preferentially engraft in vivo [36]. 
Another level of heterogeneity exists between MSCs donors and was described in
terms of their capacity for differentiation and growth in vitro  [37] as well as in vivo
performance [38]. The differences were attributed to the variations in isolation procedure
[37] and  recently  it  was  shown  that  the  in  vivo  performance  of  MSCs  positively
correlates with the expression levels of TSG-6 gene [38].
One of striking examples of interspecies differences is the one between mouse
and human MSCs [39]. When similar conditions are used, mouse MSCs contain larger
population of hematopoetic contamination and exhibit prolonged lag phase [40].
It  has  been shown that  MSCs can  be  isolated  from various  tissues  including
adipose tissue, dental pulp, placenta, amniotic fluid and many others in addition to bone
marrow [41].
The omnipresence of MSCs and their heterogeneity raises a question about their
origin. Currently two main theories are recognized.
First theory suggests that MSCs are perivascular cells or pericytes [42], [43]. It is
supported  by  the  fact  that  MSCs  can  be  isolated  from virtually  any tissue  and  the
presence of common markers, such as CD146 [44]. Second theory suggests that MSCs
take origin from neuroectoderm via epithelial-to-mesenchymal transition  [45].  It  was
shown that mouse bone marrow contains MSCs-like cells that share a common marker
with neuroepithelial cells – Nestin [46]. These cells were shown to support hematopoesis
and have the ability to  differentiate  into  bone fat  and cartilage  similar  to  MSCs.  In
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support  of  epithelial-to-mesenchymal  transition  theory  it  has  also  been  shown  that
introduction of TWIST gene drives epithelial cells toward mesenchymal differentiation
[47].
I.3 MSCs in in vivo models of diseases
One of the major driving forces behind the interest in MSCs is their potential
benefits in clinical applications. As mentioned in earlier parts of the introduction 439
clinical trials are being conducted with MSCs. The majority are phase 2 and 3 trials (258
and 278 respectively). Phase 0, 3 and 4 have 7, 33 and 1 trials respectively.
The impressive spread of conditions that MSCs are being used for in the clinic
represents the evolution of paradigms for repair of tissues by MSCs  [48]. Thus, early
paradigms were based on the multipotentiality of MSCs and their ability to support the
hematopoetic  niche.  It  was  proposed  that  MSCs  would  replenish  or  substitute  the
deficient cells in the host by means of engraftment. In one of the initial studies beneficial
effects of MSCs administration and their subsequent engraftment was shown in children
with osteogenesis imperfecta – a congenital condition, characterized by brittle bones and
frequent  fractures  [49],  [50].  Furthermore,  systemic  administration  of  MSCs  had  a
positive effect in models of kidney injury, myocardial infarction, stroke and others [51]–
[53]. However, it has been extensively shown that beneficial effects of MSCs occur with
minimal or temporary engraftment [54], [55].
The notion that MSCs support and organize hematopoetic niche formed the basis
for co-administration of MSCs during hematopoetic stem cell transplantation [56], [57].
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The later  paradigms emerged from observations  that  MSCs exhibit  beneficial
effects with limited engraftment. Among the modes of action that fall under this category
are cell-to-cell contact and fusion of MSCs with host cells and production of secreted
factors.
Spees et al. showed that human MSCs rescue small airway epithelial cells that are
devoid of mitochondria by means of fusion and transfer of mitochondria [58]. The latter
was also shown in vivo in a model of LPS-induced lung injury [59].
Direct cell-to-cell  contact has been shown important in glial  differentiation of
neural  stem  cells  in  a  co-culture  system  with  MSCs  [60].  Contact  of  MSCs  with
macrophages was necessary for reprogramming them into non-inflammatory phenotype
[61].
Secreted factors, produced by MSCs can be classified by their mode of action:
anti-apoptotic, pro-regenerative and anti-inflammatory/immunomodulatory [62].
The anti-apoptotic effect of MSCs was recently attributed to the production of a
secreted  protein  called  stanniocalcin-1  (STC-1)  [63].  This  protein  exhibits  its  action
through inhibition of oxidative stress via uncoupling oxidative phophorylation  [64]. It
has been shown that MSCs produce the protein both in vitro upon co-culture with lung
epithelial cells and in vivo in aggregates formed in peritoneal cavity [65].
Several factors secreted by MSCs could be classified as pro-regenerative as they
promote  local  vasculo-  and  angiogenesis  (EGF  and  VEGF)  or  recruit  local  tissue
progenitors  (SDF-1,  IGF-1).  The  production  of  these  factors  by  MSCs  was  shown
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beneficial in models of myocardial infarction  [66]–[68], acute kidney injury [51], [69]
and brain injury [70]–[73].
One of the qualities of MSCs is their ability to modulate the inflammation. The
research  in  this  area  was  pioneered  in  early  2000's  by  Katarina  Le  Blanc  and  her
colleagues  [74] who  showed  that  MSCs  inhibit  stimulation  of  mixed  lymphocyte
reaction (MLR) in vitro and independently from her by Bartholomew et al.  [75] who
demonstrated the inhibition of MLR but also inhibition of skin graft rejection due to
MSCs administration in vivo.
Since  these  two  pioneering  studies,  a  plethora  of  anti-inflammatory  factors
produced  by  MSCs  were  discovered.  Few  molecules  attracted  more  attention  from
researchers than the others and will be reviewed here.
Indoleamine 2,3-Dioxygenase (IDO) was shown to be produced by MSCs after
their exposure to IFN-γ in vitro  [76]. IDO is known to inhibit T-cell proliferation by
local depletion of tryptophan and production of its toxic derivative kynurenine [77]. In
support, human MSCs have been shown to inhibit T-cell activation and proliferation both
in  in  vitro  [76] and  in  vivo  models  of  heart  and  kidney  transplantation  [78],  [79].
However, only human MSCs are known to utilize this mechanism. MSCs isolated from
rodents were shown to utilize immunosuppressive mechanism via production of NO by
iNOS [80]. Interestingly, as with the IDO in human MSCs, IFN- γ stimulation is required
for NO production.
Prostaglandin E2 was shown to be produced by human and mouse MSCs  [61],
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[81]. The production of PGE2 by MSCs is dependent on their stimulation with TNF-α,
LPS, IL6  [82] or by MSCs aggregation in  vitro  [81] and in vivo  [65].  PGE2-related
inhibition  of  inflammation  occurs  via  several  ways,  including  conversion  of  M1
macrophages to  the M2 phenotype  [61],  suppression of T-cells  proliferation  [83],and
induction of T-reg differentiation [84].
As it was mentioned in previous sections, the systemic administration of MSCs in
immunocompromized  mice  results  in  the  embolization  of  lung  vasculature  [54] and
stimulation of MSCs to produce anti-inflammatory protein TSG-6. This 35 kDA protein,
originally discovered in fibroblasts,  was previously shown to inhibit  inflammation in
models of arthritis, air pouch and others reviewed in  [85]. TSG-6 produced by human
MSCs was shown to be beneficial in models of myocardial infarction [54], LPS-induced
lung  injury  [86],  corneal  inflammation  [87] and  zymosan-induced  peritonitis  [88].
Although its mechanism of action is not completely understood, it was proposed that
TSG-6  could  stabilize  the  pro-inflammatory  fragments  of  hyaluronan  or  inhibit
translocation  of  NFκB  via  direct  or  indirect  interaction  with  CD44  [88],  inhibit
neutrophil infiltration [89] and others (reviewed in [85]).
I.4 Systemic routes of delivery and MSCs biodistribution
Various routes of MSCs administration are being used in preclinical studies. They
can be categorized as systemic, local and specialized methods of delivery such as by
association with scaffold [90].
The majority of  studies  utilize  the  systemic  route of  delivery via  intravenous
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injection. Immediately after the injection MSCs distribute to lungs and few other organs
[54],  [55].  Although  the  exact  fate  of  MSCs in  those  organs  is  not  described,  it  is
believed that the cells respond to local cues, such as pro-inflammatory cytokines [54]. In
turn, MSCs upregulate the expression of genes, such as TSG-6  [54], [86] and COX2
[61]. The intravenous route of injection proved to be beneficial in myocardial infarction
model  [54], [55], corneal injury model  [91], LPS-induced lung injury  [86], [92], [93],
bleomycin lung injury [18], [94] and many others.
Intraperitoneal (IP) administration could be placed in both categories – local and
systemic based on the studied disease model. Thus, it was shown that in model of colitis,
IP-injected MSCs migrate toward inflamed colon and don't leave peritoneal cavity [95],
however other studies showed the presence of MSCs in virtually all organs after their
administration  inside  peritoneal  cavity  [96],  [97].  In  addition,  it  was  shown that  IP
administration  of  MSCs results  in  formation  of  MSCs spheroids  [65] similar  to  the
spheroids  formed  in  vitro   [98].  Formation  of  spheroids  was  associated  with  the
upregulation of the expression of TSG-6, STC-1 and COX2 genes [65]. The production
of these and other factors by MSCs in peritoneal cavity could be linked to distant effects
of MSCs in models of inflammation [86], [91], [99].
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CHAPTER II
REVERSIBLE COMMITMENT TO DIFFERENTIATION BY HUMAN
MULTIPOTENT STROMAL CELLS IN SINGLE-CELL–DERIVED COLONIES*
II.1 Overview
II.1.1 Objective
Human multipotent stromal cells readily form single-cell–derived colonies when
plated at clonal densities. However, the colonies are heterogeneous because cells from a
colony form new colonies that vary in size and differentiation potential when replated at
clonal  densities.  The  experiments  here  tested  the  hypothesis  that  cells  in  the  inner
regions of colonies are partially differentiated, but the differentiation is reversible.
II.1.2 Materials and Methods
Cells were separately isolated from the dense inner (IN) regions and less-dense
outer  regions  (OUT)  of  single-cell–derived  colonies.  Cells  were  then  compared  by
assays of their transcriptomes and proteins, and for clonogenicity and differentiation.
II.1.3 Results
IN  cells  expressed  fewer  cell-cycle  genes  and  higher  levels  of  genes  for
extracellular matrix than the OUT cells.  When transferred to differentiation medium,
differentiation of the colonies occurred primarily in the IN regions. However, the IN
* Reprinted with permission from “Reversible Commitment To Differentiation By Human 
Multipotent Stromal Cells In Single-Cell–Derived Colonies” by Joni Ylostalo, Nikolay Bazhanov, 
Darwin J Prockop, 2008, Experimental Hematology, Volume 36, Issue 10, Pages 1390-1402, 
Copyright 2008 by Elsevier.
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cells  were  indistinguishable  from  OUT cells  when  replated  at  clonal  densities  and
assayed for rates of propagation and clonogenicity. Also, colonies formed by IN cells
were similar to colonies formed by OUT cells because they had distinct IN and OUT
regions.  Cultures  of  IN  and  OUT cells  remained  indistinguishable  through  multiple
passages  (30  to  75  population  doublings),  and both  cells  formed colonies  that  were
looser and less dense as they were expanded.
II.1.4 Conclusions
The  results  demonstrated  that  cells  in  the  IN  region  of  single-cell–derived
colonies are partially differentiated, but the differentiation can be reversed by replating
the cells at clonal densities.
II.2 Introduction
There is currently interest in both the biology and potential therapeutic uses of the
adult stem/progenitor cells from bone marrow, referred to in initial reports as fibroblastic
colony-forming units (CFU-F), then in the hematological literature as marrow stromal
cells,  subsequently  as  mesenchymal  stem  cells,  and  most  recently  as  multipotent
mesenchymal stromal cells or MSCs [30]. Although there is general agreement that the
cells  can  be  isolated  as  the  plastic  adherent  cells  from human  marrow,  there  is  no
consensus as to how the cells should be expanded in culture. In particular, there has been
no consensus as to whether cells in culture are homogeneous  [5], [10], [100]. Human
MSCs  (hMSCs)  that  are  expanded  as  confluent  cultures  appear  homogeneous  [5],
[101] and  several  antibodies  have  been  developed  to  surface  epitopes  on  confluent
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cultures of MSCs [102]–[111]. In contrast to studies on confluent cultures of hMSCs, a
number  of  reports  emphasized  the  heterogeneity  of  earlier  stage  cultures.  Early
investigators observed that the first cells that appear in low-density cultures are spindle-
shaped, and they are replaced by much larger and flatter cells as the cultures mature
[112]. Evidence for heterogeneity of MSCs was subsequently emphasized by expansion
of the cells at low density. When adherent cells initially isolated by plating mononuclear
cells from bone marrow were replated at low densities of about 1 to 100 cells/cm2, the
cells underwent dramatic changes in morphology, rates of proliferation, and patterns of
gene expression as they expand in culture  [33]. MSCs from low-density cultures were
readily cloned as single cell–derived colonies [6], [10], [100], [101], [113], [114], and up
to 90% of the MSCs generated colonies when tested by a single-cell CFU-F assay [115].
Some of the single-cell–derived colonies differentiated into osteoblasts, adipocytes, or
chondrocytes in culture, but some of the colonies were less multipotential. Low-density
cultures contained both small, rapidly self-renewing cells (RS-MSCs) and larger, more
slowly  replicating  cells.  Cultures  enriched  for  RS-MSCs  had  a  greater  potential  to
differentiate  than cultures of the large,  mature cells.  Also,  RS-MSCs engrafted more
efficiently in immunodeficient mice  [36]. The confluent cultures of the large,  mature
cells continued to secrete a number of growth factors, an observation consistent with
their  ability  to  serve  as  feeder  layers  for  hematopoietic  stem/progenitor  cells.
Remarkably, if the cultures were harvested before they reached confluency and replated
at low density, the sequence of events repeated itself in that the cells initially were RS-
12
MSCs and  these  gradually  were  replaced  by slowly  replicating  cells.  The  sequence
repeated itself through several passages until the cells approached senescence. Here we
report  that  single-cell–derived  colonies  are  heterogeneous  because  cells  in  the  inner
regions (IN) differed from cells in the outer regions (OUT) in terms of morphology and
their commitment to differentiation. However, the differences disappear if the cells are
replated at clonal densities. 
II.3 Materials and methods
II.3.1 Human MSCs isolation and expansion
Human MSCs were obtained from the Tulane  Center  for  the  Preparation and
Distribution  of  Adult  Stem Cells  (http://www.som.tulane.edu/gene_therapy/distribute).
Human MSCs were isolated and expanded as described previously  [34]. Preparations
were standardized because they demonstrated trilineage differentiation in culture, were
negative for hematopoietic markers (<1% for CD34, -36, -45, and -117), and positive for
several general markers for MSCs (>95% for CD29, -44, -49c, -59 -90, -105, -147, and
-166).  For experiments here,  a  frozen vial  of MSCs (donor 5064, 7012 or 240) was
thawed and  cells  were  plated  in  a  145-cm2 culture  dish  (Nunc)  in  complete  culture
medium (CCM):  a-minimal  essential  medium (αMEM; GIBCO/BRL,  Carlsbad,  CA,
USA), 17% fetal bovine serum (FBS) lot selected for rapid growth of MSCs (Atlanta
Biologicals, Norcross, GA, USA), 100 U/mL penicillin, 100 mg/mL streptomycin, and 2
mM L-glutamine (GIBCO/BRL).  After  24-hour incubation at  37ºC and 5% CO2,  the
medium was removed, cells  were washed with phosphate-buffered saline (PBS),  and
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adherent  viable  cells  were harvested with 0.25% trypsin and 1 mM ethylenediamine
tetraacetic acid (EDTA) for 5 minutes at 37ºC as recovered passage 1 cells. 
II.3.2 Time-lapse microscopy
Recovered passage 1 MSCs (donor 5064) were plated onto 57-cm2 dishes (Nunc)
at 0.5 cells/cm2 and incubated at 37ºC and 5% CO2 without medium change. After 2
hours, adherent single cells on a plate were marked with a scratch on the bottom of the
plate  under  light  microscopy.  Pictures of partially overlapping fields  of  view around
initial  cell location were taken every 24 hours for 11 days by phase contrast  (Nikon
digital camera DXM 1200F; Kawasaki,  Japan, attached to Nikon Eclipse microscope
TE200; Japan). Multiple images were combined into one image using Adobe Photoshop
6.0.1. (Adobe Systems Inc., San Jose, CA, USA).
II.3.3 Laser capture microdissection of IN and OUT regions of colonies
Recovered passage 1 MSCs (donor 5064) were plated at  2  cells/cm2 on laser
capture  microdissection  and  pressure  catapulting  (LMPC)  slides  (PALM
MembraneSlides  NF,  P.A.L.M.  Microlaser  Technologies  GmbH;  Bernried,  Germany)
that were placed into 57cm2 plastic dishes (Nunc). Cells were cultured for 10 to 12 days
in CCM at 37ºC and 5% CO2 without medium change until dense colonies that were at
least 4 mm in diameter were observed. Slides were washed with PBS, fixed with ice-
cold 100% ethanol, and dried. Colonies with distinct OUT and IN regions were outlined
and  laser  microdissected  (P.A.L.M.  MicroBeam  System  with  UV  laser,  P.A.L.M.
RoboMover, driven by Palmwin software 2.2 and Zeiss Axiovert S-100 microscope; Carl
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Zeiss MicroImaging GmbH, Oberkochen, Germany). Dissected OUT or IN cells from
two colonies were catapulted separately into one cap, filled with 20 µL extraction buffer
(PicoPure RNA Isolation Kit;  Molecular  Devices,  Sunnyvale,  CA, USA). Cells  were
spun down at 800g for 2 minutes,  mixed by pipetting, and incubated at 42ºC for 30
minutes before cooling to 4ºC and extracting total RNA.
II.3.4 Isolation of live cells from OUT or IN regions of colonies
Recovered passage 1 MSCs (donors 5064, 7012, and 240) were plated onto 57-
cm2 plastic dishes (Nunc) at  2 cells/cm2 and incubated at  37ºC and 5% CO2 without
medium change for 10 to 12 days. Colonies that were selected for the isolation were
similar in size (at least 4 mm in diameter), round morphologies, distinct dense IN and
less-dense OUT regions with readily distinguishable cell phenotypes in each region. The
cell  phenotypes of the OUT regions were thin,  spindle-shaped cells rarely contacting
with each other; while the major population of the IN region composed of bigger cells,
that were in contact with each other but not overlapping and that formed linear streams
of cells,  oriented  toward OUT region.  Before  isolation,  5  to  12 OUT regions  or  IN
regions were outlined with marker. To isolate the OUT region of the colony, the central
region was destroyed with pipette tip. The cells from the IN region of the colony were
isolated after scraping the OUT region with a cell scraper (Corning, Lowell, MA, USA).
Dishes were washed with PBS, and cloning cylinders (Bel-Art Products, Pequannock,
NJ, USA) with grease (Dow Corning 7 Release Compound; Dow Corning, MI, USA)
were placed over the outlined region (either IN or OUT of the colony). Cells in the
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inside of the cloning cylinder were harvested with trypsin/EDTA. From 8 to 12 colonies
from one or more plates were pooled for OUT region sample, while 5 to 8 were pooled
for IN region sample. Samples were centrifuged at 1000g for 6 minutes and washed with
PBS, followed by centrifugation. Cells were either used for RNA isolation or used for
growth curve, CFU-F, or subcloning assays.
II.3.5 RNA isolation and quality
IN and OUT cells were isolated from colonies of MSCs from donor 5064 by
LMPC and from donors 7012 and 240 by live cell isolation method. Total RNA was
extracted (PicoPure RNA Isolation Kit) with DNase treatment (RNase-Free DNase Set,
Qiagen,  Germantown,  MD,  USA).  Amount  and  quality  of  isolated  total  RNA  was
measured either by spectrophotometric assay (SmartSpec 3000; Bio-Rad, Hercules, CA,
USA)  or  capillary  electrophoresis  (Agilent  2100  Bioanalyzer;  Agilent  Technologies,
Waldbronn,  Germany)  using  RNA 6000  Pico  kit  (Agilent)  and  RNA 6000  Ladder
(Ambion, Austin, TX, USA). The 18S and 28S ribosomal RNA peaks were identified on
the electrophorogram, and RNA Integrity Numbers  (RINs) were calculated using the
Bioanalyzer software. Six samples, three from the IN region (1 IN, 2 IN, and 5 IN) of
colonies and three from the OUT region (2 OUT, 4 OUT, and 5 OUT) of colonies (donor
5064),  with  at  least  20  ng  total  RNA and  RIN  of  at  least  8.5,  were  chosen  for
microarrays. 
II.3.5 Microarray assays
Ten nanograms total RNA from each sample (three IN and three OUT samples)
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were  used  in  the  amplification  and  labeling  steps  according  to  manufacturer’s
instructions  (Ovation  Biotin  RNA  Amplification  and  Labeling  System,  NuGEN
Technologies, San Carlos, CA, USA). The amount of biotin-labeled cDNA was assayed
by spectrophotometer (SmartSpec 3000). Biotin-labeled cDNA (1.6 to 2.2 µg) from the
six  separate  samples  were  hybridized  on  the  microarrays  (HG-U133  Plus  2.0;
Affymetrix, Santa Clara, CA, USA) and processed as described previously [34]. Scanned
images  were  transferred  to  the  dChip  program  [116]–[118].  Arrays  were normalized
using the invariant set normalization method and model-based expression values were
calculated using the signal from perfect match and mismatch probes. Negative values
were  assigned  a  value  of  one.  Genes  were  considered  significantly  different  in
expression between IN and OUT samples if they had at least a twofold difference (with
90% confidence), were present in all the samples where the gene was upregulated, and
had a t-test p-value of 0.05 or lower between groups (IN vs OUT). The 199 transcripts
(155 nonredundant genes based on Gene ID) that were significantly different were used
in  hierarchical  clustering  of  the  samples  and  genes  [119],  [120].  The  resulting  two
patterns of expression from the IN and OUT regions were examined for Gene Ontology
(GO) term enrichment [121]. Next, p-values were calculated for each GO term based on
the exact hypergeometric distribution, to compare the frequencies of GO terms within
each pattern to their frequencies across the entire microarray (p<0.01 were considered
significant). Microarray data will be available at the Gene Expression Omnibus database
(http://www.ncbi.nlm.nih.gov/geo/). 
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II.3.6 Real-time RT-PCR
Total RNA (40 ng) samples from IN and OUT regions of colonies from the three
donors  were converted  into  cDNA (High-Capacity cDNA Reverse Transcription  Kit;
Applied Biosystems, Foster City, CA). A custom-designed card (TaqMan Low Density
Array;  Applied  Biosystems)  was  used  to  perform  real-time  reverse  transcriptase
polymerase  chain  reaction  (RT-PCR)  [34].  Sample  preparation  and  analysis  was
performed as described previously [34].
II.3.7 Immunocytochemistry
Recovered passage 1 MSCs (donor 5064) were plated onto 57-cm2 plastic dishes
or  6-well  plates  (Nunc)  at  2  cells/cm2 and  incubated  at  37ºC  and  5% CO2 without
medium change.  On day 12,  cultures  were  washed with  PBS,  fixed  in  ice-cold  4%
paraformaldehyde (Electron Microscopy Sciences, Hatfield, PA, USA) for 15 minutes,
and washed again. 
For  labeling  with  MKI67 (antigen  identified  by monoclonal  antibody Ki-67),
cells were permeabilized with 0.5% Triton X-100 (Sigma, St Louis, MO, USA) in PBS
for 15 minutes at room temperature. The remaining samples were not permeabilized.
Cells  were  washed  and  blocked  with  3%  bovine  serum  albumin  (Albumin  bovine
fraction V; Sigma) in PBS for 1 hour at room temperature. After blocking step, areas of
interest were outlined, sealed with aqua-hold barrier pen (Scientific Device Laboratory,
Des Plaines, IL, USA), and incubated with 400 µL primary antibody in PBS and 1%
bovine serum albumin for 20 hours at 4ºC in a humidified chamber. The buffer for anti-
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MKI67 also contained 0.025% Triton X-100. The primary antibodies were: 10  µg/mL
mouse monoclonal anti-human-KI67 (IgG1 clone Ki-S5; Chemicon International, Inc.,
Temecula,  CA, USA);  2  µg/mL mouse  monoclonal  anti-human-VCAM1 [IgG1 clone
BBIG-V1(4B2); R&D Systems, Minneapolis, MN, USA]; and 4 µg/mL goat polyclonal
antihuman – PODXL (podocalyxin-like) (IgG1; R&D Systems). Mouse monoclonal IgG1
(clone 11711; R&D Systems) in the same concentrations as the primary antibodies was
used as the isotype control. After incubation with the primary antibody, slides were cut
out of plastic dishes using heated blade. Slides were washed in PBS and incubated with
400  µL containing 2  µg/mL secondary fluorescence-conjugated antibody (Alexa fluor-
488 goat anti-mouse IgG (H + L), or Alexa fluor 594 donkey anti goat IgG (H + L);
Molecular Probes, Eugene, OR, USA) in PBS with 1% bovine serum albumin for 1 hour
at room temperature. For permeabilized samples, the buffer contained 0.025% of Triton
X-100. After washing with PBS, slides were mounted with VECTASHIELD Mounting
Medium  with  DAPI  (Vector  Laboratories,  Burlingame,  CA,  USA),  covered  with
coverslips and sealed. Analysis was performed using Nikon Eclipse E800 microscope
with attached SPOT color 2.2.0 digital camera (Diagnostic Instruments, Sterling Heights,
MI, USA) using SPOT version 3.1 software. The same settings were used to acquire
control-labeled images and all pictures on the slide. Subsequent image manipulations
were made in Adobe Photoshop 6.0.1.
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II.3.7 Differentiation within colonies
Recovered passage 1 MSCs (donor 7012) were plated onto 57-cm2 plastic dishes
(Nunc) at 2 cells/cm2 and incubated at 37ºC and 5% CO2 in CCM for 9 days without
medium change. On day 9, cultures were washed with PBS and the medium on different
plates  was  replaced  with  either  CCM  (control),  adipogenic  medium,  or  osteogenic
medium.  Adipogenic  medium  consisted  of  CCM  supplemented  with  0.5  µM
dexamethasone  (Sigma),  0.5  µM  3-isobutyl-1-methylxanthine  (Sigma),  and  50  µM
indomethacin (Sigma). Osteogenesis medium consisted of CCM supplemented with 1
nM  dexamethasone,  20  mM  b-glycerolphosphate,  50  µg/ml  L-ascorbic  acid-2-
phosphate. CCM and differentiation media were changed every 3 days for 21 days. After
21 days, cultures were washed with PBS and fixed in formalin at room temperature for 1
hour. To stain lipid droplets within the cells, adipogenic cultures were washed with PBS,
incubated with 0.3% Oil-Red-O (Sigma) solution for 20 minutes at room temperature,
and washed again. To stain the sites of mineralization, osteogenic cultures were washed
with water, incubated with 1% Alizarin Red S solution (Sigma) for 20 minutes at room
temperature, and washed again. 
II.3.8 Growth curve assay
To study the growth kinetics, MSCs isolated from the whole colony and different
colony regions (donor 5064) were plated in CCM at 100 cells/cm2 onto 6-well dishes
(Nunc) in triplicate. Cells were incubated for 1 to 12 days with medium change every 3
days.  For  counting,  cells  on  individual  wells  were  washed  with  PBS,  lifted  with
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trypsin/EDTA, washed with CCM by centrifugation, and resuspended in 0.4% Trypan
Blue (GIBCO/BRL) before counting in a hemacytometer. 
II.3.9 Subcloning and CFU-F assays
To study clonogenicity, cells (donors 5064, 240, and 7012) initially isolated either
from the OUT region or the IN region were plated at 2 cells/cm2 onto 57-cm2 dishes
(Nunc) in CCM. After 10 to 12 days without medium change, IN regions were isolated
from  colonies  generated  from  IN  regions  and  replated.  The  same  procedure  was
performed with colonies generated from OUT regions. Subcloning was continued until
colonies were no longer compact with distinct IN and OUT regions for up to five cycles
of isolation and replating. CFU-F assays from the same cell preparations in each cycle
were done in parallel and in triplicate. On day 14, plates were washed with PBS and
stained with 3% crystal violet (SigmaAldrich, Inc.) in 100% methanol for 5 minutes,
washed with water, and air-dried. Stained colonies that were at least 2 mm in diameter
were  counted.  Percentage  of  colonies  per  plate  was  obtained  using  total  number  of
colonies and initial amount of the cells plated. For densitometry, pictures of partially
overlapping fields of colonies (donor 7012) at 40 magnification were taken with ORCA
digital  camera  (ORCA,  ER,  Hamamatsu,  Japan)  attached  to  an  inverted  microscope
(Nikon Eclise, TE200 Nikon). Final image was obtained by combining multiple images
into one using ImageJ 1.38x software. After conversion into 8-bit grayscale format and
background subtraction, gray intensity values were obtained for each pixel through the
diameter of the colony. The pixels were then plotted against their correspondent gray
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intensity values in Excel (Microsoft Corporation, Redmond, WA, USA). Sliding window
of 50 pixels was used for smoothing. Images of differentiated colonies were created by
combining  pictures  of  partially  overlapping  fields  of  view  taken  by phase  contrast.
Multiple images were combined into one using Adobe Photoshop 6.0.1. Linear image
adjustments  were  performed by varying brightness  and contrast  in  order  to  improve
image visibility without changing original image structure.
II.4. Results
II.4.1 Expansion of a single-cell–derived colony
To follow expansion of single cells into colonies, vials of frozen passage 1 MSCs
(donor 5064) were thawed, plated overnight to recover viable adherent cells, replated at
0.5 cells/cm2 on 57-cm2 plastic dishes, and time-lapse photomicrographs taken by phase
microscopy. Single adherent cells that were spindle-shaped were detected within 2 hours
(Fig. 1). To follow expansion, the areas containing single cells were marked by scratches
on the bottom of the plate. Expansion of a single cell into a typical colony is presented in
Figure 1. Two cells were seen in the same area on day 1, and the number increased until
day 12. Round, refractile cells in mitosis were visible in the photomicrographs as white
spots mostly in the periphery of the colony. On days 4 to 6, the cells remained spindle-
shaped with a minimum of cell-to-cell contacts. By day 12, the cells at the center of the
colony were confluent, but nonconfluent spindle-shaped cells were present around the
periphery of the colony. 
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Figure 1. Expansion of a single-cell–derived colony. Recovered passage 1 human multipotent 
stromal cells (MSCs) (donor 5064) were plated at 0.5 cells/cm2 and incubated for 12 days without 
medium change. Phase photomicrographs were taken approximately every 24 hours for 12 days. 
Location of single cell after 2-hour incubation was marked by right angle cuts on bottom of dish. 
Scale bar: 500 µm. Arrows: single cells after 2 hour and 1 day incubation.
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II.4.2 Differences in mRNA expressed by cells in the center and periphery of 
colonies
Separate samples of cells in the center (IN, 3 samples) and periphery (OUT, 3
samples) of colonies (donor 5064) were isolated by LMPC (Fig. 2A, B, C), RNA was
extracted, amplified, and the expressed mRNAs assayed with microarrays. A capillary
electrophoretic assay demonstrated that the extracted RNA was intact showing distinct
28S and 18S peaks without background (Fig. A-1). Total of 199 differentially expressed
transcripts (155 non-redundant genes) were identified and used in hierarchical clustering
of the samples and genes (Fig. 2D, Tables A-1, A-2). The data clearly distinguished the
OUT samples from the IN samples from a series of separately analyzed colonies. Cells
derived from the IN cells of the colony expressed higher levels of genes for extracellular
matrix and inorganic anion transport (p<0.001) (Fig. 2D). 
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Figure 2. Isolation and microarray assays of inner (IN) and outer (OUT) samples. Multipotent 
stromal cells (MSCs) (donor 5064) were incubated on laser microdissection slides at 2 cells/cm2 for 
12 days without medium change. Cells from IN and OUT were isolated with laser capture 
microdissection and pressure catapulting (LMPC). The colonies in the figure were stained with 
crystal violet for illustrative purposes only. (A) Intact colony. (B) Colony after IN was captured. (C) 
Colony after IN and OUT were captured. (D) Heat map of microarray data from IN and OUT samples
using 199 differentially expressed genes. Enriched GeneOntology terms with p<0.001 are shown for 
both clusters. On the heat map, red indicates upregulation and blue downregulation based on gene-
wise standardized values. Three OUT samples (2OUT, 4OUT, 5OUT) and three IN samples (1IN, 
2IN, 5IN) were used in the microarray assays. Scale bar in (A), (B), and (C): 500 µm. AURKB – 
aurora kinase B; CDC – cell division cycle; COL21A1 – collagen type 21 a1; ESPL – extra spindle 
pole bodies homolog; FGF – fibroblast growth factor; GPC – glypican; GTSE – G2 and S-phase 
expressed; H2AFX – H2A histone family member X; IN – inner region of a colony; LAMA – 
laminin-a; LUM – lumican; MKI67 – antigen identified by monoclonal antibody Ki-67; MYB – v-
myb myeloblastosis viral oncogene homolog; OUT – outer region of a colony; POLE – polymerase 
epsilon; SGOL – shugoshin-like; SPAG – sperm-associated antigen; TACC – transforming acidic 
coiled coil-containing protein; THBS – thrombospondin
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Figure 2 (continued)
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The OUT cells from the periphery expressed higher levels of genes for cell cycle
and division, mitosis, growth factor activity, protein binding, and non-membrane–bound
organelle  (p<0.001)  (Fig.  2D).  In  the  IN  cells,  the  extracellular  matrix  molecules
upregulated  included  thrombospondin  2  (THBS2),  laminin  a4  (LAMA4),  lumican
(LUM), glypican 4 (GPC4), and a1 chain of collagen III (COL3A1), VIII (COL8A1, XII
(COL12A1), and XXI (COL21A1) (Table A-1). In the OUT cells, the cell-division genes
upregulated included cell-division cycle homologs 20 (CDC20) and 25 (CDC25), cell-
division  cycle–associated  3  (CDCA3)  and  5  (CDCA5),  aurora  kinase  B  (AURKB),
sperm-associated antigen 5 (SPAG5),  extra  spindle pole bodies homolog 1 (ESPL1),
centromere protein J (CENPJ), and shugoshin-like 1 (SGOL1) (Table A-1).
To confirm the microarray data, the same samples of RNA were assayed by real-
time RT-PCR. Data identified 28 genes upregulated in IN sample relative to the OUT
sample and 15 genes showed significant upregulation in the OUT sample compared to
the IN sample (Fig. 3A and B). Comparison of data from the real-time RT-PCR assays
with data from the microarray data indicated similar differences in the genes expressed
by IN and OUT cells  (Fig.  3A and B).  However,  real-time RT-PCR assay was more
sensitive to differences in that 16/28 IN genes and 4/15 OUT genes in the microarray
assay did not reach the threshold level of a twofold difference. Based on the real-time
RT-PCR  assays  the  largest  changes  in  the  IN  sample  were  vascular  cell-adhesion
molecule-1 (VCAM-1) (10.6-fold upregulation), THBS2 (9.9-fold upregulation), LUM
(9.0-fold  upregulation),  growth  arrest-specific  1  (GAS1)  (8.1-fold  upregulation),  and
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galactosidase b1 (GLB1) (6.7-fold upregulation). The largest changes in the OUT sample
were the antigen identified by monoclonal antibody Ki-67 (MKI67 or Ki67) (32.5-fold
upregulation),  hyaluronan-mediated  motility  receptor  (HMMR or  CD168)  (30.0-fold
upregulation),  AURKB (14.8-fold upregulation),  podocalyxin-like (PODXL) (7.2-fold
upregulation), and leukemia inhibitory factor (LIF) (7.2-fold upregulation). 
To confirm the  results,  real-time  RT-PCR assays  were  performed on colonies
generated by MSCs from two additional donors (7012 and 240 in Fig. 3C and D). As
expected  from  previous  reports  [34],  variations  were  observed  with  samples  from
different donors (Fig. 3C and D), but the results were similar for 60% (9 of 15) of the
upregulated OUT genes and 32% (9 of 28) of the upregulated IN genes (Fig. 3C and D).
Also,  IN  cells  from all  the  donors  expressed  much  higher  levels  of  two  genes  for
extracellular matrix proteins (THBS2 and LUM) and the GAS1. 
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Figure 3. Assays of mRNA from inner (IN) and outer (OUT) regions by microarrays and real-
time reverse transcriptase polymerase chain reaction (RT-PCR). Total RNA was isolated from IN
and OUT cells obtained with laser capture microdissection and pressure catapulting (LMPC) (donor 
5064) or live cell isolation method (donors 7012 and 240). Genes shown have significant changes in 
their expression based on real-time RT-PCR. (A) Genes upregulated in the OUT sample (donor 
5064). (B) Genes upregulated in the IN sample (donor 5064). (C) Genes upregulated in the OUT 
region of all three donors (5064, 7012, and 240). (D) Genes upregulated in the IN region of all three 
donors. Values are fold changes. *Not significant in the microarray assays (less than twofold). Error 
bars: 95% confidence intervals; n = 3. AGC = aggrecan; ANGPT = angiopoietin; AURKB = aurora 
kinase B; CCND = cyclin D; CTNNB = catenin-b; CXCL12 = CXC chemokine ligand 12; DCN = 
decorin; DKK = dickkopf homolog; E2F7 = E2F transcription factor 7; FGF = fibroblast growth 
factor; FZD = frizzled homolog; GAPDH = glyceraldehyde-3-phosphate dehydrogenase; GAS = 
growth arrest-specific; GDF = growth differentiation factor; GLB = galactosidase-b; GPC = glypican;
GSN = gelsolin; HMMR = hyaluronan-mediated motility receptor; IL = interleukin; IN = inner region
of a colony; ITGA = integrin-a; LIF = leukemia inhibitory factor; LPXN = leupaxin; LUM = 
lumican; MCM = minichromosome maintenance deficient; MKI67 = antigen identified by 
monoclonal antibody Ki-67; MMP = matrix metalloproteinase; NOTCH = notch homolog; OUT = 
outer region of a colony; PODXL = podocalyxin-like; RARB = retinoic acid receptor beta; RUNX = 
runt-related transcription factor; SOCS = suppressor of cytokine signaling; SOX = sex-determining 
region Y-box; STAT = signal transducer and activator of transcription; SYNPO = synaptopodin; 
SYTL = synaptotagmin-like; THBS = thrombospondin; VCAM = vascular cell-adhesion molecule; 
VIL = villin; WNT = wingless-type MMTV integration site; WWTR = ww domain containing 
transcription regulator. 
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Figure 3 (continued)
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II.4.3 Differences demonstrated by immunocytochemistry
Immunocytochemistry of the colonies confirmed that OUT cells expressed higher
levels of MKI67, a marker for proliferating cells, and PODXL, a marker for motile cells 
(Fig. 4). Immunostaining also confirmed that the IN cells expressed higher levels of cell-
adhesion molecule VCAM-1 (Fig. 4). These results suggest that within colonies the OUT
cells are proliferating more rapidly than the IN cells. 
Figure 4. Immunocytochemistry of MKI67, PODXL, and VCAM-1 in colonies. Three regions of 
multipotent stromal cell (MSCs) colonies from donor 5064 are shown. Nuclear counterstain: DAPI. 
Insets: enlarged regions of the same slides. Magnification: x40, x100 (insets). MKI67 = antigen 
identified by monoclonal antibody Ki-67; PODXL = podocalyxin-like; VCAM-15 = vascular cell-
adhesion molecule-1.
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II.4.4 Differentiation of colonies
To study the  differentiation  capability  of  IN and OUT cells  within  a  colony,
MSCs colonies were cultured under adipogenic and osteogenic conditions for 21 days.
Colonies grown under adipogenic conditions and stained with OilRed-O showed lipid
droplets preferably in the IN cells (Fig. 5). Similarly, colonies grown under osteogenic
conditions and stained with Alizarin Red S showed sites of mineralization mainly in the
IN region (Fig. 5). The results further confirmed the observations that the IN cells were
more committed to differentiation than OUT cells. The cells in the OUT region have the
morphology of fibroblasts that is characteristic of MSCs plated at a low density [112]. 
Figure 5. Differentiation of colonies. Representative colonies (donor 7012) after adipogenic or 
osteogenic differentiation. Colonies were fixed with formalin and stained with either Oil-Red-O 
(adipogenesis) or Alizarin Red S (osteogenesis). Under both conditions, differentiation initiated in the
inner (IN) regions of the colonies. Scale bar: 1 mm.
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II.4.4 Similar rates of proliferation on IN and OUT cells on replating
To compare the proliferation potential of IN and OUT cells, MSCs were plated on
plastic dishes and the two fractions separated by scraping away either the IN or OUT
cells of colonies and lifting the remaining cells with a cloning cylinder. The cells were
replated  at  100  cells/cm2 and  incubated  for  up  to  12  days.  The  IN  and  OUT cells
proliferated at essentially the same rate (Fig. 6A). Also the doubling times as a function
of days in culture were essentially the same with the peak of proliferation around day 3
(Fig. 6A).
II.4.5 Clonogenicity of IN and OUT cells
To  compare  their  clonogenicity,  cells  from  all  three  donors  were  grown  as
previously, and the IN and OUT cells were isolated from passage 2 colonies and replated
at low density. The IN and OUT cells from passage 3 were isolated and replated at low
density. The sequence was repeated until the cells did not generate colonies with distinct
IN and OUT regions (Fig. A-2). Results were analyzed by both the number of colonies
generated (CFUs) and the morphology of the colonies.
There were no significant differences in CFU values obtained for IN and OUT
cells  from passage  3  with  MSCs from the  three  donors  (Fig.  6B).  As expected  [6],
however, there was decrease in CFUs with further passages with a distinct decrease with
some preparations of MSCs. Colonies with distinct IN and OUT regions were obtained
until passage 7 with MSCs from donor 5064, and passage 6 with MSCs from donor 240,
but only until passage 4 with MSCs donor 7012. 
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Figure 6. Expansion and clonogenicity of isolated inner (IN) and outer (OUT) cells. Multipotent 
stromal cell (MSCs) (donors 5064, 7012, and 240) were plated at 2 cells/cm2 and incubated for 10 to 
12 days. Cells (passage 2) were isolated either from the OUT or the IN and replated at 100 cells/cm2 
for growth curve assay and at 2 cells/cm2 for fibroblastic colony-forming units (CFU-F) assay. (A) 
Growth curve assay for donor 5064. Inset: Fold changes per day. (B) CFU-F assays of cells from IN 
and OUT of all three donors. Subcloning was continued for up to five cycles of isolation and 
replating (passage 7). Error bars: standard deviations; n = 3. P = passage.
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To assess the morphology of the colonies generated, we classified colonies with 
diameters of 4 mm or more with distinct IN and OUT regions as type I and smaller 
colonies or loose large colonies as type II (Fig. 7A). The distinctions between the two 
types of colonies that were apparent by phase microscopy were readily confirmed by 
densitometry of dye-stained colonies (Fig. A-3). With MSCs from all three donors, the 
fraction of type I colonies decreased upon subcloning while the fraction of type II 
increased (Fig. 7B, C, and D). There were no apparent differences between the IN and 
OUT samples. Interestingly, type II colonies became majority at passage 6 for donor 
5064 (Fig. 7B), at passage 5 for donor 240 (Fig. 7C), and at passage 4 for donor 7012 
(Fig. 7D). Similarly, the size distribution of colonies in all three donors shifted toward 
smaller diameter colonies upon passaging (Fig. 8A, B, and C).
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Figure 7. Changes in colony morphology upon subcloning. Multipotent stromal cell (MSCs) 
colonies were stained with crystal violet, measured, and classified either as type I or type II. Type I 
colonies were at least 4 mm in size with a dense inner (IN) region. Type II colonies were either <4 
mm in size with dense IN region or larger but loose. (A) Representative large and small type I 
colonies (upper panel) and type II colonies (lower panel) from one culture dish of donor 240 MSCs 
(passage 3). See Fig. A-3 for densitometry of stained type I and type II colonies. Distribution of type I
and II colonies during subcloning for donor: (B) 5064, (C) 240, and (D) 7012. Error bars: standard 
deviations; n = 3. Scale bar: 1 mm. CFU-F=colony-forming unit fibroblast; IN = inner region of a 
colony; OUT = outer region of a colony; P = passage.
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Figure 7 (continued)
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Figure 8.  Colony size distribution upon subcloning. Multipotent  stromal cell  (MSCs)  colonies
were divided into four groups based on their size (2.0 –3.5 mm, 4.0 – 5.5 mm, 6.0 – 7.5 mm, and 8.0
– 9.5 mm). Size distribution of colonies derived from donor: (A) 5064, (B) 240, and (C) 7012. Error
bars: standard deviations; n = 3. IN = inner region of a colony; OUT = outer region of a colony; P =
passage.
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II.5 Discussion
As originally noted by Friedenstein et al.  [27], one of the characteristic features
of MSCs cultures is their clonal growth, i.e., their ability to form distinct single-cell–
derived colonies after  plating at  very low densities  [5],  [27],  [101].  Previous reports
demonstrated that the single-cell–derived colonies of MSCs vary in morphology, growth
rates, and differentiation capacity [6], [100], [122]. In addition, MicroSAGE analysis of
single-cell–derived colonies showed that MSCs expressed mRNAs common to different
mesenchymal  cell  lineages,  suggesting  heterogeneity  within  a  colony  [123].  In  the
present study, we focused on the observation that most early culture single-cell–derived
colonies had very high–density IN regions, and less-dense OUT regions. Cells in the
OUT region have the morphology of fibroblasts that is characteristic of MSCs plated at a
low density. Microarray assays demonstrated that cells in the IN region expressed many
genes for extracellular matrix, and cells in the OUT region expressed genes involved in
cell  cycle  and division.  Validation  of  microarray data  with  real-time RT-PCR assays
indicated a good correlation between these two methods. However, real-time RT-PCR
assays were more sensitive because they detected changes that were not significant in the
microarray assays.  Also,  the changes in  several  genes  detected by real-time RT-PCR
were much larger than microarray data suggested. The differences may be explained, in
part, by the fact that the real-time RT-PCR assay did not require amplification of the
RNA. We demonstrated differences in protein expression by immunocytochemistry of
colonies confirming the mRNA data in that the IN cells expressed higher levels of the
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cell-adhesion protein (VCAM-1), while the OUT cells expressed higher levels of the
cell-cycle  protein  (MKI67),  suggesting  that  within  colonies  the  OUT  cells  are
proliferating more rapidly than the IN cells. OUT cells also expressed higher levels of an
antiadhesion protein (PODXL), which is a member of the CD34 family of sialomucins
and has been identified in undifferentiated human embryonic and hematopoietic stem
cells  [124]–[127].  In  addition,  PODXL has  been  shown  to  increase  the  aggressive
phenotype  of  malignant  cells  and  thus  could  be  important  in  MSCs  migration  and
survival in vivo  [128]. Recently,  we identified higher expression of PODXL in early
cultures of MSCs compared to late cultures, suggesting PODXL as a marker of highly
proliferative early culture MSCs  [34]. Interestingly, the OUT cells resemble the early
culture MSCs in their gene expression patterns, while the IN cells are more similar to the
late  culture  MSCs  [34].  Therefore,  results  suggested  that  the  IN  cells  were  more
committed  to  mesenchymal  differentiation  than  the  OUT cells.  The  suggestion  was
confirmed  by  transferring  the  colonies  to  differentiating  in  conditions  in  which,  in
agreement  with previous  observations  [100],  differentiation  into  both  adipocytes  and
osteoblasts initially occurred in the IN regions of colonies. However, when IN cells were
replated at clonal densities, the IN cells were indistinguishable from OUT cells in their
rates of propagation, clonogenicity, and formation of colonies with distinct IN and OUT
regions.  Therefore,  results  indicated  that  partial  differentiation  of  the  IN  cells  was
reversible. Proliferation of MSCs is limited by density in culture and, therefore, probably
in vivo under physiological and pathological conditions. The heterogeneity and plasticity
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observed in  the  cultures  suggest  that  the  protocols  used  to  expand human MSCs in
culture may have a major influence on how efficiently the cells engraft and repair tissues
in animal models and in patients [36]. 
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CHAPTER III
ADULT HUMAN MESENCHYMAL STEM CELLS FROM BONE MARROW
PREVENT FUNCTIONAL DECLINE AND DECREASE INFLAMMATION IN
MOUSE MODEL OF HCl-INDUCED LUNG INJURY
III.1 Overview
III.1.2 Rationale
Gastric  aspiration  is  the  fourth  leading  cause  of  acute  respiratory  distress
syndrome characterized by uncontrolled inflammation resulting in high mortality rates
among patients.  In  current  study we used the  hydrochloric  acid  (HCl)-induced  lung
injury model  to  mimic  the  conditions  of  gastric  aspiration.  Here  we tested  whether
human  mesenchymal  stem  cells  from  bone  marrow  (MSCs),  known  for  their  anti-
inflammatory  and  immune-modulatory  properties,  could  prevent  the  decline  in  lung
function by reducing inflammation in the lungs of injured mice.
III.1.3 Methods
HCl was administered via tracheal intubation in 0.3% NaCl into BALB/C mice.
Immediately after the injury the animals received intraperitoneal (IP) or intravenous (IV)
injections of human MSCs (3 million in Hanks Balanced Salt Solution) or recombinant
human TSG-6 protein or vehicle alone. Lung function was monitored by pulse-oximetry
until  day  4  post-injury.  Infiltration  of  alveolar  spaces  by  inflammatory  cells  was
evaluated by flow-cytometry of bronchoalveolar lavage (BALF). ELISAs were used to
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determine concentrations of pro-and anti-inflammatory markers in BALF.
III.1.4 Results
Injury with HCl resulted in sharp decline in gas exchange function as assayed by
pulse oximetry. There was a significant drop in the arterial oxygen saturation (SpO2)
levels  within  4  hours  post-injury,  accompanied  by significant  decrease  in  heart  and
breath rates. The changes corresponded to the development of inflammation in the lungs
including increases in protein content, amount of infiltrating cells in BALF, and increase
in IL6. Intraperitoneal  but not intravenous administration of human MSCs prevented
decrease of SpO2 levels below 90%. Both intraperitoneal administration of MSCs and
recombinant human TSG-6 significantly reduced total number of infiltrating cells and
pro-inflammatory cytokines such as IL6, TNF-α, and CXCL-1 in alveolar spaces.
III.1.5 Conclusions
Intraperitoneal administration of human MSCs prevented decline in lung function
and  reduced  inflammation  in  mice  injured  with  HCl.  Intravenous  administration  of
MSCs failed to produce beneficial  effect while administration of human recombinant
TSG-6 resulted in  inhibition of  inflammation in  the lungs but  did not  improve their
function.
III.2 Introduction
Acute respiratory distress syndrome is clinically defined by acute onset, bilateral
lung opacities,  not  explained by other  factors,  respiratory failure  of  non-cardiogenic
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origin,  and decreased oxygenation,  according to  the most  recent Berlin  classification
[129].  Former  classification  identified  ARDS as  a  severe  form of  acute  lung injury,
which had similar  definition with lesser  extent  of  reduced oxygenation  [130].  Acute
respiratory distress syndrome is one of the leading causes in for ICU hospitalizations.
Approximately 190,000 patients are hospitalized with ARDS annually with 3.6 million
hospital days  [131]. The mortality rates for patients with ARDS were estimated to be
around 20% in 2005-2006, according to the most recent ARDS Network clinical trials
[132].
Various  factors  can  cause ARDS, most  common include bacterial  pneumonia,
sepsis, aspiration of gastric contents and shock [133]. The major underlying pathological
mechanism of ARDS is damage to alveolar epithelium either directly from pathogenic
factors, such as bacteria or microbial  products  [134] or by effectors of inflammatory
pathways  such  as  neutrophils  [135] or  platelets  [136].  The  damage  is  followed  by
activation of innate immune system in the lungs and the production of pro-inflammatory
cytokines such as TNF-α, IL6 and others. This in turn increases vascular permeability,
causing  alveolar  edema  and  recruiting  immune  cells  from systemic  circulation.  The
inflammatory response,  initially directed to  clear the alveolar spaces from the injury
becomes excessive and uncontrolled and exacerbates the injury [137]. 
Clinically,  ARDS  progresses  through  several  phases  that  correspond  to  the
development or resolution of underlying inflammation [138]. The early exudative phase
is characterized by edema and the development of hallmark hyaline membranes, that
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consist mostly of fibrin and detritus. Interstitial inflammation develops concomitant with
the appearance of hyaline membranes  ultimately progressing into interstitial  fibrosis.
Inflammation, disruption of alveolar-capillary barrier and edema cause the progression
of hypoxemia. The resolution of ALI and ARDS involves proliferation of fibroblasts and
regeneration of  alveolar  epithelium during proliferative phase,  which  progresses  into
fibrotic stage characterized by the development of collagen deposits.
Despite  significant  research  in  ARDS,  only  two  therapeutic  approaches  were
shown to be effective in reducing the mortality to 26% from 40% - protective low-tidal
volume ventilation and fluid conservation therapy [133]. Therefore, there is a need for
novel and effective therapeutic approaches.
Recently,  human  mesenchymal  stem  cell  (MSCs)  emerged  as  potential
therapeutic  option  for  treatment  of  ALI  and  ARDS.  Thus,  human  MSCs  and  their
products were beneficial in pre-clinical studies of LPS-induced lung injury in mice [59],
[86], [139] and in ex-vivo perfused human lungs [140], bleomycin-induced lung injury
[18], [94] and ventilator -induced lung injury [141].
The results from these and other studies indicated that human MSCs are being
activated in vivo by signals and factors from injured tissues. This activation leads to
production  of  various  factors  many  of  which  have  anti-inflammatory  and
immunomodulatory activity (reviewed in [62]). TNF-α-stimulated gene/protein 6 (TSG-
6) was identified among other factors produced by activated MSCs  [54]. TSG-6 is 35
kDa protein originally identified in TNF-α stimulated fibroblasts  [142]. It is a potent
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anti-inflammatory mediator and its production by MSCs has been shown to partially
explain their beneficial effects in models of myocardial infarction  [54], corneal injury
[91] and lung injury by LPS [86].
Despite the large scope of investigation, the effects of human MSCs have not
been studied in models of HCl-induced lung injury. This model mimics the condition
known  in  humans  as  aspiration-induced  lung  injury,  where  alveolar  and  bronchial
epithelium is  being injured by acid contents of gastric  juice  [143].  This condition is
acknowledged as one of the leading causes of ARDS  [133] and leads to the series of
inflammatory events in the lungs described above.
Here, we test the effects of MSCs and human recombinant TSG-6 in a model
HCl-induced lung injury. We evaluated the effect of MSCs and TSG-6 on lung function
after the injury by pulse-oximetry assay and inflammation by cytokine ELISA assay.
The results demonstrated beneficial effects on lung function and inflammation if
MSCs are administered intraperitoneally immediately after the insult with HCl. Human
recombinant TSG-6 was shown to improve inflammation in the lungs.
III.3 Material and methods
III.3.1 Mesenchymal stem cells
Mesenchymal stem cells were obtained from the Center for the Preparation and
Distribution  of  Adult  Stem  Cells  (http://medicine.tamhsc.edu/irm/MSCs-
distribution.  html) Human MSCs were isolated were prepared as previously described
[144]. In brief, after thawing about 1 million passage 1 MSCs were plated in complete
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culture  medium  (CCM)  consisting  of  α-minimum  essential  medium  (MEM,  Gibco,
Grand Island, NY), 17% fetal bovine serum (FBS, Atlanta Biologicals, Lawrenceville,
GA), 100 units/mL penicillin (Gibco), 100 mg/mL streptomycin (Gibco), and 2 mM L-
glutamine (Gibco) on a 152 cm2 culture dish (Corning, Acton, MA) for 24 hours. Cells
were washed with phosphate buffered saline (PBS) and the adherent viable cells were
harvested  using  0.25%  trypsin  and  1  mM  ethylenediaminetetraacetic  acid  (EDTA,
Gibco) for 3–4 minutes at 37°C, reseeded at 100–200 cells/cm2 in CCM and incubated
for 6–7 days (with medium change every 2-3 days) before freezing in αMEM containing
30% FBS and 5% dimethylsulfoxide (Sigma, St. Louis, MO). For the experiments, the
cells  were  recovered  as  passage  2,  cultured  for  24  hours,  and  replated  at  100–200
cells/cm2.  The  cells  were  cultured  for  6–7  days  and  harvested  with  trypsin-EDTA,
washed  once  in  Hanks  Balanced  Salt  Solution  (HBSS,  Lonza,  Basel,  Switzerland)
containing 0.1% FBS and then again washed with serum-free HBSS. The cells were
finally reconstituted at 1 x 104 cells/μl to a total amount of 0.3–3 x 106 cells in serum-
free HBSS and kept on ice for the injections.
III.3.2 Animals
An animal use protocol was approved by the Texas A&M Health Science Center
Institutional Animal Care and Use Committee at Scott and White Hospital. Male 6- to 8-
wk-old wild-type (BALB/c) mice obtained from Jackson Laboratories were used for this
study. The mice were kept on a 12-h light-dark cycle and fed and watered ad libitum.
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III.3.3 Hydrochloric-induced lung injury
Hydrochloric acid (HCl, Sigma-Aldrich) at pH 1.2-1.5 was prepared by slowly
adding  its  concentrated  stock  solution  to  0.3% NaCl  (Sigma-Aldrich).  The  level  of
acidity was monitored by table-top pH-meter (VWR), that was appropriately calibrated
to include the range of pH at 1.3-1.5. The HCl solutions were then filtered via 0.22
micron filter (VWR), aliquoted in sterile tubes and stored at room temperature until the
administration into animals. Random tubes of HCl were tested for the acidity before the
animal experiment to ensure the pH.
The  administration  of  hydrochloric  acid  was  performed  via  intubation  as
previously described [145]. In brief, mice were anesthetized with isoflurane to reach the
level  of  deep  anesthesia  and  placed  on  the  intubation  stand  facing  upward  at
approximately 45°. With the aid of external light source the trachea was intubated with a
22-G plastic sterile IV catheter (Terumo). Hydrochloric acid or 0.3% sodium chloride
alone (sham injury) was instilled through a catheter at volume 4 µl/g body weight in two
sets.
At 15 minutes after the injury mice received one of the following treatments:
recombinant  human  TSG-6 (R&D Systems)  (50  µg  in  50  –  150  µl  of  sterile  PBS)
intravenously,  human MSCs (250,000-750,000 in  100  µl  of  HBSS) intravenously or
human MSCs (3,000,000 in 300  µl of HBSS) intraperitoneally or appropriate vehicle
control.
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III.3.4 Blood, tissue and bronchoalveolar lavage fluid collection
Mice were deeply anesthetized with isoflurane and euthanized by intraperitoneal
injections of ketamine-xylazine solution at 80 and 8 mg/kg body weight, respectively.
Blood, tissue and bronchoalveolar lavage was collected as described in  [145]. In brief,
blood was collected first from the right heart ventricle into clotting-activator-coated tube
(Terumo Medical, Somerset, NJ) and used to prepare serum by centrifuging the tube at
1,500 g for 10 min. To collect bronchoalveolar lavage fluid the lungs were flushed with
PBS via 20-G plastic iv catheter placed inside the trachea (Exelint, LosAngeles, CA).
Two sets of lavage were obtained. The first set, collected by flushing the lungs with 800
µl of PBS was used for cytokine analysis, while second set, collected by flushing the
lungs with 4 ml of PBS was used for cellular analysis and flow cytometry.  The lavage
fluid was centrifuged at 500 g for 10 min at 4°C to obtain a cell pellet and then spun
again at  10,000 g for 10 min to prepare for cytokine analysis. Red blood cells were
depleted by incubating the pellets at room temperature with red blood cell lysis buffer
(eBioscience, San Diego, CA) for 5 min and then washing with ice-cold PBS twice. The
cell pellet was then resuspended in PBS with 1% bovine serum albumin (BSA) (Thermo
Fisher  Scientific)  and  used  for  flow  cytometry  analysis.  The  lungs  were  collected
immediately after obtaining BALF, frozen and stored in -80°C.
III.3.5 Flow cytometry
The flow cytometry was performed as previously described  [145]. Briefly, the
non-specific  binding  to  Fc-receptors  was  blocked  by  with  anti-CD16/32  antibody
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(eBioscience)  at concentration 0.5 µg per 1x106 cells in 100 µl  of PBS with 1% BSA.
The cells were then incubated for 20 min at room temperature with both phycoerythrin-
Cy7-conjugated anti-mouse F4/80 antibody (eBioscience) and FITC-conjugated anti-Ly-
6G antibody (BD Pharmingen, San Diego, CA) at concentration of 1 µg per 1x106 cells
in 100 µl of PBS with  1% BSA. Isotype-matching antibodies at similar concentrations
obtained from the same manufacturers and single-color labeling were used as controls
for  the  specificity  of  labeling.  After  two  washes  in  PBS,  the  cells  were  again
resuspended in PBS-1% BSA and analyzed by FC500 flow cytometer (Beckman Coulter,
Brea, CA) to determine macrophage (F4/80-positive) and neutrophil  (Ly-6G-positive)
populations.
III.3.6 Cytokine ELISA in BALF
Cytokine  ELISAs in  BALF was  performed  as  previously described  [145].  In
brief, lung protein concentration was determined by using Micro BCA Protein Assay Kit
(ThermoFisher  Scientific)  according  to  the  manufacturer’s  instructions.  Cytokine
concentrations  were  determined  by  using  commercially  available  ELISA  kits  for
detection  of  IL-6,  TNF-α,  IL-1,  CCL2/MCP-1,  CCL3/MIP-1α,  CXCL2/MIP-2,  and
CXCL1/KC  (R&D  Systems,  Minneapolis,  MN)  according  to  the  manufacturer’s
instructions.
III.3.7 Pulse oximetry
Pulse  oximetry  was  performed  as  previously  described  [145] using  portable
mouse  pulse  oximeter  (STARR  Life  Sciences).  Briefly,  the  collars  of  experimental
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animals were trimmed and extra-small MouseOX collar clip was placed on the animal’s
neck. SpO2, heart and breath rates  were recorded during “calm” phase  [145] at 15-Hz
sample  rate.  The  measurements  and  data  extraction  and  analysis  was  performed  as
described before [145].
III.3.8 Statistical analysis
GraphPad Prism software (LaJoia, CA) was used to perform unpaired t-test, one-
way  ANOVA with  Bonferroni’s  post  hoc  analysis  or  log-rank  Mantel-Cox  test  for
survival proportions. Null hypotheses were rejected at P values less than 0.05.
III.4 Results
III.4.1 Acidity of HCl solution affects functional outcome after the injury
Acute lung injury in mice was produced by intratracheal instillation of HCl in
0.3% NaCl with pH range of 1.3-1.5. There was a marked difference in survival rate
between pH 1.3 and other groups (Fig. 9A). The harshest condition was pH 1.3, where
none of the injured animals survived after 24 hours mark. In contrast, animals injured
with HCl at pH 1.5 did not show mortality until 3 days after the injury. Furthermore,
only 40% of the animals injured with HCl at pH 1.4 survived past 24 hours. 
Oxygen saturation levels dropped significantly in the first 8 hours in all groups
with the most  dramatic  drop in  pH 1.3 group. These changes  were accompanied by
pronounced reduction in heart (Fig. 9C) and breath rates (Fig. 9D). The SpO2 values
gradually returned to normal around day 3, while heart and breath rates recovered by day
2 in all groups. No significant changes in SpO2, heart and breath rates were observed in
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control group instilled with 0.3% NaCl.
We chose HCl with pH 1.5 for further experiments because it decreased SpO2
without affecting survival in the first 24 hours.
Figure 9. Functional changes in hydrochloric acid (HCl)-induced lung injury. HCl in 0.3% NaCl
with pH range of 1.3-1.5 was instilled via intubation into the lungs of adult male Balb/C mice. Pulse
oximetry was performed over the course of 5 days. (A) Survival rate of mice injured with HCl at
indicated pH. Dynamics of oxygen saturation levels (B), heart rate (C) and breath rate (D) after the
injury with HCl at indicated pH. Number of animals within each group range between 3 to 6. The
values represent arithmetic mean or individual data points, error bars – SEM. 
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Figure 10. Dynamic changes in BALF following injury with HCl pH 1.5. (A) Total cells, F4/80
positive macrophages and Ly6G-positive neutrophils in BALF after injury with HCl at pH 1.5 (B).
Total protein, (C) IL-6 cytokine and (D) IL-10 cytokine levels after HCl injury. Number of animals
within each group range between 3 to 6. The values represent arithmetic mean or individual data
points, error bars – SEM. * p <0.05, **, p<0.01 
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III.4.2 Dynamic changes in BALF following injury with HCl pH 1.5 
Following the injury with HCl pH 1.5 we observed increase in total BAL cell
number at 4 – 24 hours post injury and highest number of neutrophils at 12 hours (Fig.
10A). Macrophages decreased initially but then gradually increased between 12 – 24
hours (Fig. 10A). Likewise, the highest protein concentration (Fig. 10B) and IL-6 (Fig.
10C) cytokine expression were observed at 12 hrs, while IL-10 (Fig. 10D) levels were
lowest at the same time point and increased at 24 hours after the onset of the injury.
III.4.3 Intraperitoneal but not intravenous administration of human MSCs 
alleviates HCl-induced lung injury
Human MSCs were administered  immediately following the  injury with  HCl.
Administration  of  3  x  106 human  MSCs  inreaperitoneally  resulted  in  significant
improvement in oxygen saturation levels at 24 hours (Fig. 11A). However, mice injected
intravenously with various doses of MSCs did not show any improvement in oxygen
saturation levels over control group (Fig. 11B).
Analysis of bronchial lavage fluid showed significant decrease in BAL total cell
number  and  neutrophils  in  animals  at  24  hours  after  administration  of  MSCs
intraperitoneally (Figs.  12A and B).  Proinflammatory cytokines  TNF-α,  IL6 and KC
were also reduced in animals after intraperitoneal administration of MSCs (Figs. 12C, D
and E). Intravenous administration of MSCs, however, did not have an effect neither on
total cells nor neutrophils in BAL (Fig. 13).
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Figure 11. Effect of IP and IV administration of human MSCs on SpO2.  Timecourse of SpO2
changes after administration of human MSCs IP (A) or IV (B).The values are arithmetic mean or
individual  data  points,  error  bars  –  SEM.  ***,  p<0.001  at  24  hours  between  HCL/MSCs  and
HCL/HBSS groups, ns- non significant changes between HCL/MSCs and HCL/HBSS groups
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Figure 12. Intraperitoneal MSCs administration reduces inflammation in the lungs. Total cells 
(A), neutrophils (B) and cytokines TNF-α (C), IL6 (D) and KC/CXCL1 (E) in BAL at 24 hours after 
the injury with HCl and administration of MSCs intraperitoneally.
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Figure 13. Effect of intravenous administration of MSCs on inflammation in the lungs. Total 
cells (A) and neutrophils (B) in BAL at 24 hours after the injury with HCl and administration of 
MSCs intravenously.
III.4.4 Systemic administration of TSG-6 inhibits inflammation in the HCl-injured
lungs
Animals  injured  with  HCl  pH  1.5  were  treated  with  TSG-6  protein  (50  μg)
administered  intravenously  immediately  after  injury.  Control  animals  received  sham
PBS.
There were no significant differences in oxygen saturation levels between TSG-6
treated and control groups at any timepoint after its administration (Fig. 14A). However,
there was a significant decrease of total number of cells (Fig. 14B) and neutrophils (Fig.
14C) in BALF at 24 hours in TSG-6 treated animals when compared to controls.
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Figure 14. Effect of TSG-6 treatment on SpO2 and inflammation in the lungs. (A) Dynamics of
SpO2 levels (B) Total cells, (C) Macrophages and (D) Neutrophils in BALF at 24 hours after the
injury and TSG-6 administration
III. 5 Discussion
Acute respiratory distress syndrome is important clinical condition because of
high hospitalization, mortality rate and associated health care cost. Currently, there are
only two effective therapeutic options that result in reduction in mortality rates: low-tidal
volume ventilation and fluid conservation therapy. Together their implementation into
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clinical  practice  reduced  the  mortality  from 40% to  20% in  the  past  decade  [133].
Therefore there is a need for therapeutic intervention that will decrease the mortality rate
below 20%.
Human MSCs represent viable therapeutic option for ARDS due to their recently
discovered anti-inflammatory and immunomodulatory capabilities. Their potential has
been demonstrated in various pre-clinical studies [146] and appears to be linked to their
activation by the signals from injured tissues to produce anti-inflammatory factors [62].
Here we tested the effects of human MSCs and their secreted protein TSG-6 in a
model  of  HCl-induced  lung  injury.  We  used  conscious  pulse-oximetry  as  described
[145] to evaluate the progression of injury and optimize the acidity of the HCl solution.
Among different strengths of the HCl solutions tested pH 1.5 caused sufficient decrease
in  oxygen  saturation  levels  without  causing  mortality  early  during  the  injury.  This
strength of  HCl was used throughout  the study.  The dynamic  of  changes  in  oxygen
saturation  levels  co-coincided  with  the  changes  in  BAL.  Thus,  the  peak  of  cellular
infiltration  was  observed  at  lowest  SpO2 readings.  Surprisingly  we  observed  rapid
decline in breathing and heart rate within 30 minutes after the injury.
We  used  two  modes  of  delivery  to  test  the  effect  of  MSCs.  Surprisingly
intravenous  administration  of  MSCs  immediately  after  the  injury  failed  to  have  a
beneficial  effect  on  lung  function  or  inflammation.  However,  intraperitoneal
administration of MSCs prevented the drop in SpO2 levels and reduced the infiltration of
neutrophils in the lungs. This finding contradicts results from the studies that showed
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positive effects of intravenous MSCs in other models of injury [18], [86], [94], [140].
The discrepancy could be explained by several factors.
First,  it  has  been shown that  intravenously injected  MSCs get  trapped in  the
microvasculature within minutes after the administration  [54], [147], [148]. Moreover,
high doses of MSCs caused mortality in the injected mice. HCl directly injures airways
which  creates  large  unventilated  areas  of  the  lungs,  due  to  compensatory
perfusion/ventilation changes  [143].  This mechanism is  different from other types of
injury  where  lung  epithelial  or  endothelial  cells  are  indirectly  injured  due  to  up-
regulation  of  pro-inflammatory  pathways.  Hence  intravenously  administered  MSCs
embolize  lung  microvasculature  in  unaffected  areas  increases  overall  damage  to  the
lungs. 
Second, intraperitoneally administered MSCs are activated in a similar manner to
intravenously-injected  cells  and  are  able  to  upregulate  genes  responsible  for  the
production  of  anti-inflammatory factors  such as  TSG-6,  PGE2 and  others  [65].  This
probably explains in part the beneficial effects of MSCs in the model as well as others
where  intraperitoneally  injected  MSCs  have  been  shown  to  be  as  effective  as  the
intravenous route [86], [91], [95], [149].
Finally,  only one donor of MSCs has been tested in this study. The variation
between MSCs donors  in  terms of  their  activity to  produce anti-inflammatory factor
TSG-6 has been recently shown by Lee at al.  [38]. Donors with lower levels of TSG-6
production performed poorly in models of corneal injury, bleomycin induced lung injury
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and zymosan-induced peritonitis. Therefore, donor variability could have contribute to
the negative effect of MSCs in this study.
The  finding  that  human recombinant  TSG-6 reduced the  inflammation  in  the
lungs  support  previous  observations  of  its  effectiveness  in  models  of  LPS-  and
bleomycin induced lung injury [86], [145].
Acute respiratory distress syndrome still  remains  one of the major  causes  for
hospitalization and has high mortality rate.  Present  therapeutic options alone are not
sufficient  in  reducing  the  rate  of  mortality.  The  results  presented  in  this  study
demonstrate  the  effectiveness  of  MSCs  treatment  in  reducing  inflammation  and
preventing  functional  decline  in  a  model  of  aspiration-induced  lung  injury.  Further
studies are necessary to evaluate the mechanism of MSCs and TSG-6 action.
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CHAPTER IV
INTRAPERITONEALLY INFUSED HUMAN MSCs FORM AGGREGATES
WITH MOUSE MACROPHAGES AND B220+ CELLS LIMITING THEIR
ACCESS TO LYMPHATICS BUT PRECONDITION THE MOUSE IMMUNITY
IV.1 Overview
Mesenchymal  stem/progenitor  cells  (MSCs)  have  shown  beneficial  effects  in
many models of diseases in part  by modulating excessive inflammatory and immune
responses.  Frequently  the  beneficial  effects  of  MSCs  persist  long  after  their
disappearance from host tissues, suggesting that MSCs interact with intermediate cells in
the  host  that  relay  or  amplify  their  effects.  The  cells  have  usually  been  injected
intravenously (IV) but beneficial effects have also been reported with intraperitoneally
(IP) injected MSCs; however, it was not clear how the cells entered the immune system
from the  peritoneum.  Here,  the  fate  of  the  human  MSCs  injected  IP into  immune-
competent  mice  was  studied.  Within  20  minutes,  individual  MSCs  were  no  longer
detected in peritoneal lavage fluid. Instead they were recovered as aggregates of varying
size that contained mouse macrophages and a few B220+  lymphocytes. After 1 day
most,  of  the  aggregates  containing  live  MSCs were  attached to  sites  throughout  the
peritoneal cavity including the omentum and mesentery.  Less than 0.05% of the live
injected cells were detected in spleen and jejunal lymph nodes. In all locations, MSCs
co-localized with mouse macrophages and B220+ lymphocytes. Attachment to omentum
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and mesentery was accompanied by the recruitment of immune cells and changes in the
production of a series of mouse cytokines. Moreover, the cytokine response to LPS was
markedly enhanced in mice preconditioned by IP administration of MSCs 3 days earlier.
In effect, the aggregation of IP injected MSCs limited their direct access to the lymphatic
system but did not prevent them from preconditioning the immune system.
IV.2 Introduction
Human mesenchymal stem/progenitor cells (MSCs) from bone marrow, adipose
tissues, placenta, umbilical cord and other tissues are currently being administered to
large  numbers  of  patients.  Over  100 clinical  trials  with  MSCs have  been  registered
[150],  and  five  have  reached  the  Phase  II  or  III  stage  of  development  [151].  In
essentially all the clinical trials and in most experiments in animal models, the cells were
administered  by intravenous (IV) injection.  However,  there  has  also been interest  in
administration by injection into the peritoneum (IP)  [152]–[154]. One advantage of IP
injection is that it avoids the highly efficient trapping of the cells in the lung observed
with IV injection, trapping that can produce emboli phenomena injuring the lung or even
causing death as seen in mice  [54]. Also IP injection allows for the administration of
larger numbers of the cells. In addition, in direct comparisons with IV administrations, IP
injected  MSCs  were  shown  to  have  comparable  or  even  more  profound  effects  in
experimental  autoimmune  encephalitis  [149],  twitcher  mice  with  globoid  cell
leukodystrophy  [155],  mice  with  cisplatin-induced  renal  injury  [156],  mice  with
experimental intestinal colitis  [95], mice with sterile inflammation of the cornea  [91],
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and mice with zymosan-induced peritonitis [87]. The beneficial effects of MSCs in these
and other disease models have been linked to the ability of the cells to modify both the
innate and acquired immune systems [25], [157].
The  peritoneal  cavity  provides  an  unusual  setting  for  immune  interactions
because it is primed to respond rapidly to bacteria that may be released by intestinal
spillage and allergens such as worms that enter the gastro-intestinal tract. The rapidity of
the response is obviously critical. It is mediated by at least two special classes of cells.
One special class is the B-1ymphocytes, particularly B-1b lymphocytes, found in the
peritoneal cavity and other sites such as the omentum that contain an unusual repertoire
of  receptors  that  allow  them to  mount  an  immediate  antibody  response  to  bacteria
without being part of the adaptive immune system  [158]. The second special class is
small cells that are found in mesentery and some other locations in the body and that are
triggered by worms and other allergens to mount a rapid Th2 response. The cells are
lineage negative and referred to as nuocytes and several other terms  [159]–[163]. The
cells  generate  an  innate  T-helper  2  (Th2)  response  characterized  by  secretion  of
interleukin 4 (IL4) that facilitates production of immunoglobulin (Ig) G1 and IgE, and by
secretion  of  interleukin  13  (IL13)  that  contributes  to  epithelial  hypertrophy  and
recruitment of eosinophils - characteristics of allergic responses [159], [162].
The peritoneal cavity is also an unusual setting for entry into the immune system,
because it participates in dynamic exchange of the fluids and cells between the cavity
and both the lymphatic system and the general circulation. The exchange occurs through
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three or four portals that breach the tight layer of basement membrane and mesothelial
cells that forms the peritoneal membrane and that covers all the organs and the walls of
the abdomen: (a) “milky spots” that are opaque, highly vascularized clusters of cells on
the surface of the omentum, the fatty organ that straddles the spleen, stomach and other
organs of the upper abdomen in mice but covers a much more extensive area in man; (b)
the draining lymphatic system contained in the stalk of mesenteric arteries and veins that
supplies the gastrointestinal tract and in the walls of the peritoneal cavity; (c) punctate
regions called lymphatic stomata on the underside of the diaphragm; and (d) the newly
discovered  small  cells  in  the  mesentery  and  other  tissues  that  mount  a  rapid  Th2
response [159]–[163]. The milky spots of the omentum [163], [164]  contain clusters of
macrophages and B1 lymphocytes that are similar to the free-floating macrophages and
B1 lymphocytes of the peritoneal cavity. The milky spots readily exchange particulate
matter and cells between the peritoneal cavity and the general circulation. They may
[165] or may not [164] contain resident dendritic cells that can activate lymphocytes, but
they can recruit T cells activated at other sites. The draining lymphatics of the mesenteric
stalk  and  peritoneal  wall  absorb  particles  from  the  gastrointestinal  tract  and  both
particles and cells from the peritoneal cavity. The lymphatic stomata on the underside of
the diaphragm consist  of a thin layer  of cuboidal  cells  that overlay large lacunae of
lymphatic  vessels  [166],  [167].  The  lacunae  drain  primarily  into  mediastinal  lymph
nodes and then to the thoracic duct and eventually the left subclavian vein.
In exploring the fate of MSCs injected into the peritoneal cavity, several groups
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of investigators observed engraftment of the cells not only into the peritoneum but also
into multiple  distal  organs  [96],  [97].  However,  the route the  cells  traveled  was not
defined. In initial efforts to follow the fate of human MSCs injected into the peritoneum,
we recently reported [65] that some of the MSCs aggregated and compacted into spheres
similar to the spheres formed after the cells were cultured in hanging drops. Here we
report  that  after  IP administration  of  MSCs  into  immunocompetent  mice,  the  cells
rapidly formed aggregates with macrophages and a few B220+ cells. The aggregates
were initially recovered in the peritoneal lavage fluid but then they slowly attached to
milky spots in the omentum and to regions of the mesentery. Apparently because of the
large size of the aggregates, few of the MSCs appeared in mesenteric lymphatic nodes, a
route  previously  shown  to  be  favored  by IP injected  splenocytes  [168].  The  MSCs
disappeared in less than a week but prompted recruitment of cells to the omentum and
peritoneal cavity that secreted both pro- and anti-immune mouse cytokines. The results
indicated therefore that IP injection of MSCs offers an unusual route to the immune
system in which the cells  are  first  assembled into aggregates  with macrophages  and
B220+ cells. The large size of the aggregates apparently gives them limited direct access
to the lymphatic system but the aggregates precondition the immune system either as
free-floating entities in the peritoneal cavity or bound to the omentum and sites in the
mesenteric membranes throughout the peritoneal cavity.
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IV.3 Materials and methods
IV.3.1 Human Mesenchymal Stem Cell Culture
Passage 1 wild-type MSCs and passage 4 Green-Fluorescent Protein expressing
MSCs (GFP-MSCs) were obtained as frozen vials from the Center for the Preparation
and  Distribution  of  Adult  Stem  Cells  (http://medicine.tamhsc.edu/irm/MSCs-
distribution.html).  Human MSCs (donors  7075,  7068,  and 7032)  were  isolated  from
bone  marrow aspirates  and  cultured  as  previously  described  [144].  In  vitro  growth,
differentiation, clonogenicity and epitope markers of MSCs preparations are summarized
in Table B-1 according to Reger and Prockop [169]. For the experiments described here,
a frozen vial of about 1 million passage 1 MSCs was plated in complete culture medium
(CCM) consisting of α-minimum essential medium (MEM, Gibco, Grand Island, NY),
17% fetal bovine serum (FBS, Atlanta Biologicals, Lawrenceville, GA), 100 units/mL
penicillin (Gibco), 100 mg/mL streptomycin (Gibco), and 2 mM L-glutamine (Gibco) on
a 152 cm2 culture dish (Corning, Acton, MA) for 24 hours. Cells  were washed with
phosphate  buffered  saline  (PBS)  and the  adherent  viable  cells  were  harvested  using
0.25%  trypsin  and  1  mM  ethylenediaminetetraacetic  acid  (EDTA,  Gibco)  for  3–4
minutes at 37°C, reseeded at 100–200 cells/cm2 in CCM and incubated for 6–7 days
(with medium change every 2-3 days) before freezing in αMEM containing 30% FBS
and 5% dimethylsulfoxide (Sigma, St. Louis, MO). For the in vivo experiments, the cells
were recovered as passage 2 (MSCs) and passage 5 (GFP-MSCs), cultured for 24 hours,
and replated at 100–200 cells/cm2. The cells were cultured for 6–7 days and harvested
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with trypsin-EDTA, washed once in Hanks Balanced Salt Solution (HBSS, Lonza, Basel,
Switzerland) containing 0.1% FBS and then again washed with serum-free HBSS. The
cells were finally reconstituted at 1 x 104 cells/μl to a total amount of 0.3–3 x 106 cells in
serum-free HBSS and kept on ice for the injections.
IV.3.2 Single GFP cell measurements in peritoneal cavity
All animal procedures were approved by the Animal Care and Use Committee of
Texas A&M University Health Science Center and in accordance with guidelines set
forth by the National Institutes of Health. 
Male 6 week-old BALB/c mice (Jackson Laboratories, West Grove, PA) were
injected IP with 3 x 106 GFP-MSCs. At 1 minute, 20 minutes, 4 hours and 72 hours after
the administration of MSCs, mice were euthanized by cervical dislocation under deep
anesthesia  and  peritoneal  lavage  was  collected  by  injecting  5  ml  of  PBS  into  the
peritoneal cavity followed by harvesting the lavage with a pipette. Ten microliters of the
lavage  were  then  placed  directly  in  Neubauer  hemocytometer  in  duplicate  and
fluorescent  and  brightfield  images  were  taken  using  inverted  Nikon  Eclipse  Ti-S
microscope (Nikon). The “Analyze Particles” plugin for ImageJ software was used to
count total and GFP-positive cells.
IV.3.3 Immunofluorescence of free-floating aggregates
Free-floating GFP+ aggregates were picked with tweezers from the peritoneal
cavity 24 hours after the IP injection of GFP-MSCs. The aggregates were washed twice
with PBS, and fixed with 2% paraformaldehyde (Affymetrix, Santa Clara, CA) in PBS
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for 2 hours. The fixed aggregates were washed twice with PBS, centrifuged at 500 x g
for 5 minutes, and incubated at 4°C overnight in 1 mL of 30% sucrose (Sigma) in 0.1 M
phosphate buffer (Sigma). After 24 hours, the aggregates were collected in 800 μL of
50% OCT (Sakura Finetek, Torrance, CA) and transferred into a histology mold. The
mold was frozen in isopentane (Sigma), chilled by liquid nitrogen and stored at -80°C.
Cryosections (6 μm) were prepared with a Microm HM560 cryostat and incubated for 20
minutes at room temperature before storing at -80°C. For the immunfluorescent staining,
sections  were  equilibrated  to  room  temperature,  fixed  again  for  10  minutes  in  2%
paraformaldehyde and washed twice in Tris-Buffered Saline with Tween (TBST, Cell
Signaling,  Beverly,  MA).  Nonspecific  antibody  binding  was  blocked  by  incubating
samples for 45 minutes in TBST supplemented with 5% BSA (Thermo Fisher Scientific,
Whaltman,  MA)  and  5% normal  serum (Thermo).  Following  two  washes  in  TBST,
samples were incubated for 24 hours at +4°C with primary antibodies to mouse CD11b
(catalog #550282;BD Pharmingen, Frankling Lakes, NJ) at 1:100 dilution in blocking
solution,  or  isotype  control  antibody.  Sections  were  washed  three  times  in  TBST,
incubated for 1 hour at room temperature with anti-rat Alexa-594 conjugated secondary
antibodies (Life Technologies, Grand island, NY) at 2 μg/ml in blocking solution, then
counterstained with 0.5 μg/ml of 4,6-diamidino-2-phenylindole (DAPI) (Sigma) in PBS
for 10 minutes. The sections were washed three times in TBST and mounted in Prolong
Gold antifade reagent (Life Technologies) overnight.
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IV.3.4 Whole mount immunofluorescence of aggregates in mesentery and omentum
Whole  omenta  or  portions  of  mesentery  with  visible  GFP+  clusters  were
removed from peritoneal cavity 24 hours after GFP-MSCs injection, washed twice with
PBS,  and  fixed  with  2% paraformaldehyde  in  PBS for  2  hours.  Fixed  tissues  were
washed twice with PBS and blocked by incubation in  TBST with 5% BSA and 5%
normal serum for 45 minutes at room temperature. Samples were washed twice with
TBST, and incubated for 24 hours at  +4°C with primary antibody to mouse CD45R
(catalog  #550286;  BD Pharmingen)  or  isotype  control  antibody at  1:100 dilution  in
blocking solution. Tissues were then washed three times in TBST, incubated for 1 hour
at  room  temperature  with  anti-rat  Alexa-594  conjugated  secondary  antibodies (Life
Technologies) at 2 μg/ml in blocking solution, then counterstained with 0.5 μg/ml of
DAPI in PBS for 10 minutes. The tissues were placed on a glass slide and covered with a
coverslip.
IV.3.5 Immunofluorescent image acquisition and manipulation
Low magnification  (1-2x)  bright-field  and GFP images  were captured  with  a
Nikon  Digital  Sight  DS-2Mv  camera  attached  to  a  SMZ800  dissecting  microscope
(Nikon, Japan). Illumatool Bright Light Systems LT 9900 (Lightools Research) with a
GFP filter set (470 nm excitation and 515 nm emission), was placed under the objective
of  the  microscope  to  visualize  GFP fluorescence.  High  magnification  images  were
obtained  using  a  Nikon  Eclipse  80i  upright  microscope  and  processed  using  NiS
Elements AR3.0 software (Nikon, Japan). All image manipulations (merging, brightness
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and contrast adjustment) were performed using ImageJ Version 1.49a (NIH, US).
IV.3.6 Real-time PCR for mouse cytokines
Mouse  omenta,  jejunal  lymph  nodes,  mesentery,  spleen  and  cell  pellet  that
included MSCs aggregates from peritoneal lavage were obtained as described above and
flash-frozen  in  liquid  nitrogen.  The tissues  were  homogenized in  Trizol  lysis  buffer
(Qiagen, Germany) and total RNA was isolated using RNeasy Lipid Tissue Mini Kit
(Qiagen) with DNA digestion step using DNAse (Qiagen). Isolated RNA was quantified
using  a  Nanodrop specrophotometer  (Thermo Fisher  Scientific)  and 0.3 – 2 μg was
converted to cDNA with High-Capacity cDNA RT Kit (Applied Biosystems, Foster City,
CA). Real-time PCR for mouse Il10, Il13, Ifng and Ptgs2 was performed using Taqman
Gene Expression Assays (Applied Biosystems) and Taqman Fast Master Mix (Applied
Biosystems)  in  triplicate  using  20 ng of  cDNA in  a  20  μl  reaction.  Real-time  PCR
reaction  was  performed  with  CFX96  Real-Time  PCR  Detection  System  (Biorad,
Hercules, CA) by incubating the reactions at 95°C for 20 seconds followed by 40 cycles
of 95°C for 1 second and 60°C for 20 seconds. Calculated delta-Ct values between gene
of interest and Gapdh were used to obtain relative expression values (2-ΔCt).
IV.3.7 Real-time PCR for assay of human cell number
To estimate the total number of human cells in omentum, jejunal lymph nodes,
mesentery,  spleen  and  peritoneal  lavage,  human  Glyceraldehyde  3-phosphate
dehydrogenase (GAPDH) expression was measured  [54],  [91].  Standard curves  were
prepared by combining known amounts of MSCs with tissues and peritoneal resident
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cells from naïve BALB/c mice. Total RNA was isolated using RNeasy Lipid Tissue Mini
Kit  (Qiagen)  with  DNA digestion  step  using  DNAse  (Qiagen).  Isolated  RNA was
quantified using Nanodrop specrophotometer (Thermo Fisher Scientific) and 0.3 – 2 μg
was converted to cDNA with High-Capacity cDNA RT Kit (Applied Biosystems, Foster
City,  CA). Real-time polymerase chain reaction (PCR) for eukaryotic  18S ribosomal
RNA and  human  GAPDH was  performed  using  Taqman  Gene  Expression  Assays
(Applied Biosystems) and Taqman Fast Master Mix (Applied Biosystems) in triplicate
using 20 ng of cDNA in a 20 μl reaction. Real-time PCR was performed with a CFX96
Real-Time PCR Detection System (Biorad, Hercules, CA) by incubating the reactions at
95°C for  20 seconds followed by 40 cycles  of  95°C for  1  second and 60°C for  20
seconds. Delta Ct values between human GAPDH and 18S were calculated and used to
generate standard curves (Fig. B-1A). Microsoft Excel was used to perform a non-linear
regression fit and obtain formulas for human cell number calculations (Table B-2). Delta
Ct values between human GAPDH and eukaryotic 18S were then obtained for samples
from MSCs -injected animals and used to calculate total cell numbers based on formulas
provided in Table B-2.
IV.3.8 Preparation of dead MSCs
Total of 3 x 106  MSCs in HBSS at 1x104 cells/μl were frozen by immersion into
liquid nitrogen followed by thawing at 37°C. These steps were repeated 3 times. The
cells were then placed on ice for injections. The viability of the cells was assayed by
trypan blue staining (Gibco) and more than 99% of the cells were positive for uptake of
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the dye.
IV.3.9 Whole tissue, blood, and peritoneal lavage fluid collection
Experimental  and control  mice  were euthanized by cervical  dislocation under
deep  anesthesia.  The  rib  cage  was  opened  and  blood  was  collected  from the  right
ventricle of the heart and placed in a tube containing clotting activators (Terumo Medical
Corporation,  Somerset,  NJ)  for  20  minutes  and  then  stored  on  ice  until  further
processing. Serum was separated by centrifugation at 1500 x g for 10 minutes and stored
at -80°C until further analysis. To obtain lavage fluid for assays of cytokines, 1 ml of
PBS containing Halt Protease inhibitor Cocktail (Thermo) was injected IP, followed by
gentle massaging and collection of fluid with a sterile pipette. Complete harvest of the
peritoneal cells was obtained by another injection of PBS (5 ml) followed by lavage
harvest. The cell suspension from both collections were separately centrifuged at 500 x g
for  10  minutes  at  4°C.  Supernatant  from  the  first  wash  was  further  clarified  by
centrifugation at  10,000 x g for 10 minutes at  4°C,  aliquoted and stored for  further
cytokine analysis at -80°C. The supernatant from the second wash was discarded and
cell  pellets  were  combined  and  homogenized  with  Trizol  lysis  buffer  (Qiagen,
Germany), flash frozen in liquid nitrogen, and stored at -80°C until further processing.
Mouse omentum, jejunal lymph nodes, mesentery, and spleen were collected and either
flash-frozen in liquid nitrogen for later RNA isolation, or placed in sterile HBSS for
enzymatic digestion.
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IV.3.10 Assays of cells in omentum
Omenta were excised from the animals and placed in HBSS with calcium- and
magnesium-containing 0.8 mg/ml dispase/collagenase, 0.2 mg/ml collagenase P and 0.1
mg/ml DNAse II (Roche Molecular Diagnostics, USA, Pleasanton, CA). The omenta
were  minced  and  incubated  at  37°C for  60  minutes  with  gentle  pipetting  every  15
minutes. The digest was then diluted 10 times with calcium and magnesium-free HBSS,
strained  via  70  μm nylon  mesh  and  centrifuged  at  500  x  g  for  5  minutes  at  room
temperature. Supernatant was discarded and cell pellet was resuspended in calcium- and
magnesium-free HBSS, centrifuged again, resuspended in HBSS containing 2% BSA,
followed by cell counting with hemocytometers. The cells were then incubated for 10
min at 4°C with anti-CD16/32 antibody at a concentration 0.5 μg per 1x106 cells in 100
μl (eBioscience) to block nonspecific binding to Fc-receptors. After one wash with PBS
supplemented with 1% BSA, the cells were incubated for 20 min at room temperature
with  fluorescently  conjugated  antibody  against  mouse  F4/80  (eBioscience),  Ly6G,
CD19,  CD3,  CD8,  CD45R  (BD  Pharmingen).  The  antibodies  were  used  at  a
concentration of 1 μg per 1x106 cells in 100 μl of PBS- supplemented with 1% BSA.
Isotype-matching  antibodies  at  similar  concentrations  obtained  from  the  same
manufacturers  and single-color  labeling,  were  used  as  controls  for  the  specificity of
labeling. After two washes in PBS, the cells were resuspended in PBS supplemented
with 1% BSA and analyzed by flow cytometer (Model FC500; Beckman Coulter, USA,
Brea, CA) to determine macrophage (F4/80-positive), neutrophil (Ly-6G-positive), T-cell
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(CD3 or CD8 positive) and B-cell (CD19 or CD45R positive) populations.
IV.3.11 In Vivo Tracking of GFP-MSCs
We used male BALB/c mice that were 6–8 weeks of age and housed on a 12-hour
light/dark cycle. Total of 2-3 x 106 GFP-MSCs were injected IP with 28G needle under
isoflurane anesthesia. At 4, 24, 72 and 168 hours the animals were euthanized and their
peritoneal cavities exposed. For the visualization of GFP-MSCs in omentum, the organs
were excised from peritoneal  cavities  and placed on a plate  with white  background.
Lumina IVIS II System (Perkin Elmer, Waltham, MA) was used to obtain fluorescent
images  of  whole  peritoneal  cavity  and  individual  omenta.  Living  Image  Software
version  4.1  (Perkin  Elmer)  was  used  for  GFP  fluorescence  analysis.  To  aid  in
visualization, the GFP signal was pseudocolored by applying logarithmic grayscale to
the whole peritoneal cavity image or by applying reverse logarithmic grayscale to the
images of omenta.
IV.3.12 Assays for mouse secreted cytokines
Mouse interleukin (IL) 6, IL10, IL12p70, interferon gamma (IFNγ), monocyte
chemotactic  protein  1  (MCP1),  chemokine  (C-X-C  motif)  ligand  1  (CXCL1),
transforming growth factor beta 1 (TGFβ1), and tumor necrosis factor alpha (TNF-α)
and  prostaglandin  E2 (PGE2),  in  peritoneal  lavage  and/or  serum,  were  assayed  with
commercial  ELISA kits  (R&D  Systems  Inc,  Minneapolis,  MN).  Mouse  IL13  was
assayed  with  commercial  ELISA kit  from Life  Technologies.  For  all  assays,  optical
density was determined on a plate reader (FLUOstar Omega; BMG Labtech, Germany)
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at  an  absorbency of  450  nm with  wavelength  correction  at  540  nm for  the  optical
imperfections on the plate.
IV.3.13 LPS injury model in mice
Male 6 week-old BALB/c mice were injected IP with 3x106 MSCs or dead MSCs,
prepared as described above. Sterile HBSS injections were used as controls. At 3 days
after the MSCs delivery, the animals were injected with LPS (Sigma) at 0.1 mg/kg of
body weight via tail vein. After 3 hours after the administration of LPS, tissues were
harvested and lavage fluid collected.
IV.3.14 Data analysis and presentation
When  comparing  two  groups,  unpaired  t-test  was  used,  whereas  one-way
ANOVA with Bonferroni’s post hoc analysis was used in multiple comparisons. One-
way ANOVA with Dunett's post-hoc analysis was used to compare groups to a control.
Null hypotheses were rejected at  P  values less than 0.05. All statistical analyses and
chart  preparations  were  performed  with  GraphPad  Prism  6  software  (GraphPad
Software, Inc., USA, La Jolla, CA). Curve fitting was performed using Microsoft Excel
Software. Images and charts were combined and annotated using Inkscape Software.
IV.4 Results
IV.4.1 Fate of human MSCs in peritoneal cavity
To study the fate of MSCs injected into the peritoneal cavity, 3 x 106 GFP-labeled
human MSCs were used in wild-type male BALB/C mice. To detect single GFP-labeled
cells in the peritoneal cavity, 5 ml of PBS was injected IP and the harvested lavage fluid
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was examined in a hemocytometer (Figs. 15A and B). One minute after injection, 75%
of  the  injected  GFP-labeled  cells  were  accounted  for  (Fig.  15A).  Surprisingly,  the
number fell to less than 10% after 20 minutes. At the same time, there was a marked
decrease  in  the  total  number  of  mouse  cells  in  the  lavage  fluid,  apparently because
macrophages and some lymphocytes in the peritoneal cavity had aggregated with the
MSCs [65]. The number of murine single cells increased by 4 hours and it continued to
increase for at least 72 hours (Fig. B-1B).
Aggregation  of  the  injected  MSCs  was  demonstrated  by  assays  of  the  pellet
obtained by low speed centrifugation (500 x g for 10 min) of the peritoneal lavage. Four
hours after injection of the MSCs, assays by real-time-PCR for human GAPDH mRNA
demonstrated that about 50% of the injected human cells were recovered in the pellet
(Fig. 15C, B-1A, Tables B-2 and B-3). However, at 1 day, only about 1 % of the injected
cells were recovered in the pellet of the peritoneal lavage (Fig. 15C), apparently because
the  aggregates  had  attached  to  the  mesentery,  omentum  and  other  surfaces  of  the
peritoneal cavity. Of special interest was that less than 1,500 or 0.05% of the injected 3 x
106 cells were found in the spleen and jejunal lymph nodes at any of the time points
examined.
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Figure 15. Fate of the IP injected MSCs in the peritoneal cavity. (A) Changes in the numbers of 
single GFP-positive cells and total single cells in the peritoneal cavity after intraperitoneal 
administration of GFP-MSCs into BALB/c mice. The cells were recovered by a 5 ml wash of 
peritoneal cavity with PBS. Resulting lavage was gently mixed and the single cells counted in a 
hemocytometer (n=4, mean +/- SEM). (B) Fluorescent images of single GFP-MSCs in 
hemocytometer chamber. Magnification 20X, (C) Total number of human cells in pellets of peritoneal
lavage (PLP), random sampling of about 25 mg or about 10% of mesentery (MT), omentum (OM), 
jejunal lymph nodes (JLN) and spleen (SP). To collect PLP, peritoneal lavage was collected by 
washing the peritoneal cavity first with 1 ml and then with 5 ml of sterile PBS. The two samples of 
lavage were centrifuged at 500 x g for 5 min and the pellets were combined. Human cells in the 
samples were assayed by real-time PCR for human GAPDH normalized to total eukaryotic 18S. Data
points represent arithmetic means +/- SEM, n=3 – 5. Insert indicates human cell numbers in the 
spleen and jejunal lymph nodes. Note dramatic differences in cell numbers between inset and large 
panel.
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Figure 15 (continued)
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To examine the fate of the injected cells further, we injected GFP-MSCs IP and
opened the peritoneal cavity to follow the distribution of the cells by in vivo fluorescent
imaging (Fig. 16). As expected from the assays of the lavage pellet (Fig. 15C), numerous
aggregates of GFP-positive cells were found as free-floating in peritoneal cavity at 4
hours (Fig. 16A, B). At 1 day, the GFP-positive aggregates appeared to have increased in
size and become attached to multiple surfaces within the peritoneal cavity. Many were
easily detached by flushing with PBS or lifting with a tweezers. However the aggregates
that attached to the omentum and to sites within the mesentery were firmly adherent and
appeared to be embedded within the tissues. At 3 days, there was a decrease in GFP-
labeled aggregates and at 7 days they were no longer detected.
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Figure 16. In vivo fluorescent imaging of GFP-MSCs in peritoneal cavity. (A) Depiction of GFP-
MSCs distribution in the peritoneal cavity of BALB/c mice 24 hours after IP administration. Yellow 
dashed lines outline GFP-positive areas (bright white) corresponding to omentum, aggregates and 
portions of mesentery. (B) Representative images of the peritoneum of BALB/c mice injected IP with
GFP-MSCs and followed by in vivo fluorescent imaging. Bright white areas correspond to the areas 
of GFP-positive cells. Logarithmic grayscale was applied to panels (A) and (B) to help in 
visualization of GFP signal.
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To examine the composition of the aggregates, GFP-MSCs were injected IP and
GFP-positive aggregates in  the peritoneal  lavage,  mesenteric  sites,  and the omentum
were isolated after 24 hours and examined (Fig. 17A). Immunofluorescent images of
sections of aggregates from the peritoneal lavage demonstrated that they were rich in
cells positive for CD11b+ (Fig. 17B), a marker for macrophages. Immunohistochemistry
of whole mounts of aggregates from mesenteric sites and the omentum demonstrated
that they were rich in B220+ cells (Fig. 17C), a marker, expressed in various immune
cells including B1 lymphocytes that are the predominant lymphocytes of the peritoneal
cavity and the omentum, macrophages, T-cells and dendritic cells. The micrographs and
a z-stack video of an aggregate from the omentum demonstrated that the GFP-MSCs
were at the center of the aggregates without any specific orientation (Video 1).
IV.4.2 The MSCs-aggregates in the omentum recruit macrophages and lymphocytes
Since the omentum was a major site for the firm attachment of the aggregates, the
organ was excised and examined. Fluorescence assays indicated that the content of GFP-
MSCs increased sharply by 4 hours, decreased by 3 days and were not detected by 7
days (Fig. 18A). As the MSCs decreased, there was a marked increase in the weight of
the omentum (Fig. 18B), the total cell content (Fig. 18C), and macrophage content (Fig.
18D),  observations  suggesting recruitment  of  macrophages and lymphocytes  into the
omentum that continued after most of the MSCs had disappeared (Fig. B-1B).
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Figure 17. Co-localization of human GFP-MSCs with immune cells in the peritoneal cavity. 
Representative immunofluorescent images of human GFP-MSCs in free-floating aggregates, and 
aggregates attached to mesentery and omentum 24 hours after their IP administration (A) In vivo low-
magnification (1.5x) images. (B) GFP-positive aggregates as shown in (A) were obtained from 
peritoneal cavity, cryosectioned and stained with CD11b antibody (magnification 20x). (C) GFP-
positive aggregates attached to mesentery and omentum were isolated with tweezers, fixed, labeled 
with B220 antibody, and examined as whole mounts (magnification 20x).
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Figure 18. IP injected MSCs localized to omentum and recruit immune cells. (A) Ex-vivo 
fluorescent images of omenta excised from GFP-MSCs-injected BALB/c mice. To help in 
visualization of GFP signal, reversed logarithmic grayscale was applied to the images. Black areas 
correspond to GFP-positive signal. Omenta were isolated from MSCs or HBSS-injected animals, 
weighed, digested and analyzed by flow cytometry. (B) Scatter plots represent weights of individual 
omenta. (C) Total cells after digestion and (D) total macrophages at 3 days after injections. Error bars
are +/- SEM. *, p<0.05; **, p<0.01; ***, p<0.001 compared to HBSS.
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IV.4.3 IP injection of MSCs triggers increased expression of murine cytokines
The IP infusion of MSCs stimulated increased secretion of a series of mouse
cytokines in a time-dependent manner (Fig. 19). Among the early responses was a peak
in IL12p70 at 4 hours that decayed slowly,  a peak of TGFβ1 at 4 hours that slowly
decayed,  and  a  sharp  peak  of  IL6  at  4  hours  (Fig.  19A).  Among  the  intermediate
responders,  IL10 had a small  peak at  4 hours and then a larger  peak at  3 days  that
paralleled the very large peak of IFNγ (Fig. 19B). TNF-α remained at very low levels but
had small  peaks  at  4 hours and 3 days.  The late  responders  IL13 and PGE2 slowly
increased  and  then  remained  at  high  levels  for  at  least  13  days  (Fig.  19C).  Small
increases in the systemic levels of IL10 and IL13 were detected at 3 days after MSCs
administration (Fig. B-2).
To examine effect of different MSCs preparations on the production of cytokines
in the peritoneal cavity, we examined cells isolated and expanded from three donors of
bone marrow with the standard protocol  employed by our NIH-sponsored center  for
preparation and distribution of MSCs. After IP injection of the cells, all  three MSCs
preparations increased the levels of mouse IL10, IL13, and PGE2 in the lavage (Fig. B-
3A).  Dose  response  data  from  one  donor  demonstrated  that  IP administration  of  3
million MSCs was more effective than lower amounts (Fig. B-3B). 
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IV.4.4 Mouse omentum is a major source of cytokines
To define the source of the cytokines detected in the lavage after injection of
MSCs,  we used real-time PCR assays  of  omentum, mesentery,  cells  from peritoneal
lavage, and jejunal lymph nodes (Fig. 19D). The results suggested that the omentum was
the major source of the increases in expression of mouse Il10, Ifng and Il13 but both the
omentum and the cells in the peritoneal lavage made major contributions to the increase
in Cox2 (cyclooxygenase; prostaglandin-endoperoxide synthase).
Human  MSCs  showed  distinct  change  in  their  gene  expression  profiles  after
administration inside peritoneal cavity. Real-time PCR assays showed upregulation of
human TGFβ1,  COX2 and TSG6 in injected cells in peritoneal cavity in comparison to
unstimulated in vitro cultures of MSCs (Fig. 19E).
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Figure 19. Production of mouse cytokines in the peritoneal cavity after MSCs administration. 
Mouse cytokines were assayed in peritoneal lavage of MSCs-injected BALB/c mice. Based on the 
timing of the cytokine production, they were categorized into (A) early- , (B) intemediate-, or (C) 
late-responding cytokines. Data are representative of 2 independent experiments. Values are 
arithmetic means +/- SEM, n= 4 – 6. (D) Relative gene expression of selected mouse cytokines in 
omentum (OM), mesentery (MT), peritoneal lavage pellet (PLP) and jejunal lymph nodes (JLN). 
Values are average gene expression values normalized to mouse Gapdh using 2-ΔCt method +/- SEM, 
n= 4 to 5. *, p<0.05; **, p<0.01; ***, p<0.001 compared to baseline expression levels. (E) Relative 
gene expression of human cytokines in omentum, mesentery, peritoneal lavage pellet and jejunal 
lymph nodes. Values are fold change of gene expression in vivo over corresponding gene expression 
in unstimulated in vitro cultures of MSCs prior to the injection into mice represented on the graph by 
dotted line. The expression values were obtained using 2-ΔΔCt method with human GAPDH as 
housekeeping control.
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Figure 19 (continued)
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IV.4.5 Pre-conditioning of the mouse immune system by IP injection of MSCs
The persistence of changes in the peritoneum suggested that the IP infusion of
MSCs had pre-conditioned the immune system of the mouse. Therefore we tested the
effects  of  challenging the  mice  with  the  bacterial  extract  LPS.  Mice  received an  IP
injection of MSCs followed by IV infusion of LPS 3 days later. Three hours after the
LPS injections, the mice were sacrificed and the lavage fluid was collected for cytokine
measurements (Fig.  20).  Among the early responding cytokines,  the pre-conditioning
enhanced  the  expression  of  IL12p70,  MCP1,  and  CXCL1  (Fig.  20A).  Among  the
intermediate responding cytokines,  pre-conditioning enhanced the levels of IL10 and
greatly enhanced the levels of IFNγ and TNF-α (Fig. 20B). MSCs pre-conditioning had
no effect on the levels of the late responding cytokines PGE2 and IL13 (Fig. 20C). Of
special importance was the observation that MSCs killed by repeated cycles of freezing
and thawing had little effect in preconditioning the immune system, an observation that
suggested an active rather than passive role of the IP delivered MSCs.
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Figure 20. Preconditioning of the mouse immune system by IP injected MSCs.  Live or dead
MSCs were injected IP into BALB/c mice 3 days prior to systemic administration of LPS. Identical
experiments  without  LPS administration  were  performed in  naïve  mice.  Mouse  cytokines  in  the
peritoneal  lavage  were  measured  at  3  days  after  MSCs  administration  and  3  hours  after  LPS
administration.  Based  on  the  timing  of  the  cytokine  production,  they  were  categorized  into  (A)
early- , (B) intermediate- , or (C) late-responding cytokines. Values represent mean +/- SEM, n = 4 –
7. *, p<0.05; **, p<0.01; ***, p<0.001 compared to vehicle controls in each experimental setting.
The Y-scale is logarithmically transformed.
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IV.5 Discussion
The results demonstrated that after human MSCs were injected into peritoneum
of  immune-competent  mice,  they  quickly  formed  aggregates  with  the  resident
macrophages and the B220+ cells of the peritoneal cavity. The aggregation was so rapid
that less than 10% of the MSCs were recovered as single cells in the peritoneal lavage
after 20 minutes. At 4 hours, about half of the injected MSCs were recovered in the
peritoneal  lavage  fluid  as  aggregates  that  were  readily  isolated  by  low  speed
centrifugation. At 1 day, only few of the aggregates containing MSCs were found in the
peritoneal lavage. Instead they were found as aggregates attached to multiple sites in the
peritoneal cavity. Most of the aggregates were loosely attached but those attached to the
omentum and sites within the mesentery were embedded within the tissues. The survival
and viability of  the  human cells  was assessed by real-time PCR for  human specific
GAPDH and measuring levels of GFP fluorescence emitted by GFP-MSCs. Both signals
indicated that the cells survived transiently and most disappeared after about 3 days.
Surprisingly, less than 1 in 3,000 (0.003%) of the injected cells were recovered in
jejunal lymph nodes or the spleen. The results present a contrast to previous observations
with IP injections of splenocytes in which most of the cells passed into the lymphatic
system  and  accumulate  in  lymph  nodes  [168].  The  results  indicated  therefore  that
apparently because  of  the  rapid  aggregation,  the  MSCs had limited  direct  access  to
lymphatics. 
One  interesting  observation  was  that  although  the  number  of  MSCs  in  the
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omentum rapidly decreased after 3 days, they initiated a cascade whereby large numbers
of mouse cells were recruited to the omentum and the organ doubled in weight. The
observations  are  probably  explained  by  the  peaks  of  the  pro-inflammatory  mouse
cytokines IL6 and IL12p70 at 4 hours and IFNγ and TNF-α at 72 hours that probably
attracted and activated macrophages.
However, the pattern of cytokines was mixed with a peak of the regulatory cell
cytokine IL10 at 4 hours, and later more sustained secretion of the Th2 cytokine IL13.
Real-time PCR assays  suggested that the aggregated cells  in omentum were a major
source of the cytokines with large increases in message levels for  Il10, Ifng,  and Il13.
The increases in cytokines in the peritoneum were reflected by more modest increases in
serum levels of IL10 and IL13. The recruitment of immune cells inside peritoneal cavity
resulted in net precondition the immune system. The recruited cells readily responded to
the  challenge  with  LPS  which  resulted  in  the  enhanced  production  of  several  pro-
inflammatory cytokines such as CXCL1,  TNF-α and others in mice that  received IP
MSCs 3 days earlier. 
Dose response curves demonstrated that a large dose of 3 million MSCs was
required  to  produce  maximal  increases  in  the  peritoneal  cytokines.  Surprisingly,
however, the samples of MSCs from three donor preparations of bone marrow were not
equally  effective.  The  variability  among  preparations  of  MSCs  may have  important
implications for clinical trials with the cells [157].
The  rapid  aggregation  of  MSCs with  macrophages  and  B220+  cells  explains
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some of the therapeutic effects previously observed with IP administration of MSCs in
animal models. As reported previously [65], the MSCs in the aggregates formed in the
peritoneum  within  4  hours  were  activated  to  express  high  levels  of  potentially
therapeutic  human genes  such as the genes for the natural anti-inflammatory protein
TSG-6, for COX2 that is a critical enzyme in the synthetic pathway for PGE2, and for
STC-1 that can reduce reactive oxygen species. The activation was more rapid than seen
with  human  MSCs  cultured  as  hanging  drops  under  conditions  in  which  the  cells
condense into spheres and it is probably accelerated by the presence of the macrophages
and B220+ cells in the aggregates. The rapid activation of human MSCs injected IP into
immuno-competent  mice  probably  explains  the  effectiveness  of  this  route  of
administration of human MSCs in two models of sterile inflammation: ethanol injury to
the cornea [91] and zymosan-induced peritonitis [88]. In cornea model, the window for
effective therapy is less than 6 hours  [87] and in the peritonitis model, the beneficial
effects were seen within 4 hours  [88]. In both models, the therapeutic responses were
linked to expression of TSG-6, since MSCs with a silencing-RNA knock down of the
TSG-6 gene  were  ineffective  and most  of  the  effects  of  MSCs were  reproduced by
administration of recombinant TSG-6. In present study we also show the upregulation of
TSG-6 in injected MSCs. Increase in COX2 and TGFβ1 mRNA in MSCs and COX2,
IL10 mRNAs in mouse tissues could provide an insight to anti-inflammatory effects of
MSCs. 
Similar rapid activations of IP MSCs may also explain some of the therapeutic
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effects  observed  in  other  models  [95],  [149],  [155],  [156].  The  MSCs  used  in  the
experiments  were  either  isogeneic  or  allogeneic  but  could  have  invoke  the  rapid
reactions of the peritoneal macrophages and B1 lymphocytes because the MSCs acted as
foreign bodies in the peritoneum, or because they had acquired foreign antigens during
their  isolation  and  expansion  in  culture.  As  shown previously  [170],  MSCs  rapidly
internalize large amounts of fetal bovine proteins from the medium used to culture the
cells and the internalized proteins stimulate immune responses after IV infusions of the
cells into mice. The isogeneic mouse MSCs used by Yousefi et al.[149], Scruggs et al.
[155], and Cheng et al. [156], were all isolated and expanded in medium containing high
concentrations of fetal bovine serum. In the Wistar rat model for induced colitis study,
Castelo-Branco  et  al.  [95] used  bone  marrow and  adipose  derived  MSCs  that  were
isolated  and  expanded  in  15%  or  20%  fetal  calf  serum.  Therefore  either  the  cells
themselves or the foreign proteins they carried could have prompted rapid aggregation
with  peritoneal  macrophages  and  B220+  cells,  and  the  subsequent  activation  of
therapeutic genes in the MSCs. Sorting out these possibilities is technically challenging
because of the tendency of mouse MSCs to undergo spontaneous transformation during
expansion in culture  [171], [172], and the extensive manipulations of MSCs in culture
required to remove internalized fetal calf proteins [170].
The longer-term effects of the IP MSCs in preconditioning the immune system
speak  to  a  complex  phenomenon  seen  frequently with  MSCs  in  which  their  effects
persist long after the cells can no longer be detected. Such “hit and run” effects have
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been seen with injection of MSCs into the hippocampus of uninjured mice [173], and in
mouse  models  for  transient  global  ischemia  [174],  acute  myocardial  infarction  [54],
diabetes [175], repair of meniscus [176], bleomycin-induced lung injury [145] and many
others (see  [157]). Under some circumstances the longer-term effects on the immune
system can be explained by the MSCs suppressing an early inflammatory phase that is
essential in triggering the acquired immunity. In others, it appears to be linked to the
MSCs  suppressing  antigen-presenting  cells  or  other  regulatory  cells  of  the  immune
system  [175]. The results here demonstrate that one route to establishing longer-term
effects  on  the  immune  system  is  through  aggregates  of  MSCs,  macrophages  and
B220+cells that bind to milky spots on the omentum and probably to similar sites on the
peritoneal membranes in the mesentery.
The finding that MSCs triggered production of pro-inflammatory cytokines after
challenge  with  systemic  LPS  contrasts  with  the  previous  observations  of  anti-
inflammatory activity of MSCs in vivo  [25],  [54],  [91],  [155].  We suggest that  the
differences can be explained by a combination of factors including the time of MSCs
administration relative to the challenge, the microenviromental conditions at the site at
which the MSCs engraft, and the nature of the challenge. In the current study, the MSCs
were injected 3 days prior to the injury in contrast with the majority of the studies where
MSCs are administered at the same time or after the injury.
One of the limitations of the present study is that human MSCs were employed in
immuno-competent mice. Therefore some of the effects can be ascribed to inflammatory
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and  immune  reactions  to  xenogeneic  cells.  However,  comparable  experiments  with
mouse  MSCs  are  limited  by  the  inability  of  the  cells  to  be  expanded  significantly
without undergoing spontaneous transformation  [171], [172]. Another limitation is that
the data did not establish whether the MSCs were more effective in preconditioning the
immune system than cells such as fibroblasts. However, the data demonstrated that three
preparations of human MSCs isolated and expanded with the same protocols varied in
their  efficacy.  Therefore  it  will  probably be  necessary to  compare  large  numbers  of
different preparations of MSCs and large numbers of control cells to establish which are
the most effective. The results did establish that live MSCs were far more effective than
dead MSCs in preconditioning the mice in their response to LPS. Therefore the results
were not explained by inflammatory or immune reactions to human cellular proteins or
cell debris.
IV.6 Conclusions
In conclusion, we demonstrated that IP injected human MSCs quickly aggregate
and the aggregates attach to mesentery, omentum and other sites in the peritoneal cavity.
In contrast, only small amounts of the cells also migrate to spleen and jejunal lymph
nodes. Aggregation and attachment to tissues was accompanied by the recruitment of
immune cells and sequential changes in the production of mouse cytokines. In effect, the
aggregation of IP injected MSCs appeared to limit their direct access to the lymphatic
system but did not prevent them from preconditioning the immune system.
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CHAPTER V
PHASE-DIRECTED THERAPY: TSG-6 TARGETED TO EARLY
INFLAMMATION IMPROVES BLEOMYCIN-INJURED LUNGS*
V.1 Overview
Previous reports  demonstrated that bleomycin-induced injury of lungs in mice
can be improved by the administration of murine multipotent adult stem/progenitor cells
(MSCs) from the bone marrow. Recently some of the beneficial effects of MSCs have
been explained by the cells being activated by signals from injured tissues to express the
inflammation  modulating  protein  TNF-α-stimulated  gene/protein  6  (TSG-6).  In  this
study,  we elected to test  the hypothesis  that  targeting the early phase of  bleomycin-
induced lung injury with systemic TSG-6 administration may produce therapeutic effects
such  as  preventing  the  deterioration  of  lung  function  and  increasing  survival  by
modulation of the inflammatory cascade. Lung injury in C57Bl/6J mice was induced by
intratracheal administration of bleomycin. Mice then received intravenous injections of
TSG-6 or sham controls. Pulse oximetry was used to monitor changes in lung function.
Cell infiltration was evaluated by flow cytometry, cytokine expression was measured by
ELISA  assays,  and  lungs  were  assessed  for  histological  attributes.  The  results
demonstrated that intravenous infusion of TSG-6 during the early inflammatory phase
*Reprinted with permission from “Phase-directed therapy: TSG-6 Targeted to Early Inflammation
Improve  Bleomycin-Injured  Lungs”  by  Andrea  M.  Foskett,  Nikolay  Bazhanov,  Xinyu  Ti,  April
Tiblow, Thomas J. Bartosh, Darwin J Prockop, 2014, Am J Physiol Lung Cell Mol Physiol, Volume
306, Issue 2, Pages L120-L131, Copyright 2008 by American Physiological Society.
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decreased cellular infiltration into alveolar spaces. Most importantly, it improved both
the subsequent decrease in arterial oxygen saturation levels and the survival of the mice.
These  findings  demonstrated  that  the  beneficial  effects  of  TSG-6  in  a  model  of
bleomycin-induced lung injury are largely explained by the protein modulating the early
inflammatory phase.  Similar  phase-directed strategy with TSG-6 or other  therapeutic
factors that MSCs produce may be useful for other lung diseases and diseases of other
organs.
V.2 Introduction
Bleomycins  are  a  family  of  antibiotics  that  are  currently  used  as
chemotherapeutic  agents  to treat germ-cell  cancers,  lymphomas, and malignancies of
head and neck  [177].  Unfortunately,  bleomycin chemotherapy is  a  frequent  cause of
interstitial  pneumonitis,  a  complex  lung  disease  that  can  progress  into  interstitial
pulmonary fibrosis with a poor clinical prognosis and high rate of mortality [178], [179].
Up to 46% of bleomycin-treated patients develop some form of lung toxicity leading to
death in 3% of treated patients [180].
Bleomycin exerts its toxic effects by intercalating into double-stranded DNA to
degrade the DNA and trigger the intrinsic apoptotic pathway [181]. Within the initial 48
h after administration, bleomycin produces damage/necrosis of the alveolar epithelium,
capillary congestion, perivascular permeability leading to edema, and the formation of
hyaline membranes  [182]–[184].  Concomitantly,  there is  an increase in inflammatory
cell infiltrates in the bronchoalveolar lavage fluid (BALF) [184], [185]. There is also a
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marked influx of immune cells such as lymphocytes during this acute phase [183], [184].
As the injury progresses, pulmonary fibrosis develops with an excessive deposition of
extracellular matrix deposition in the lung interstitium  [185]–[187]. In the long term,
there is compromised lung function with impaired transfer of oxygen and carbon dioxide
gases.
Several reports demonstrated that bleomycin-induced injury of lungs in mice can
be improved by administration of multipotent adult stem/progenitor cells referred to as
mesenchymal stem or stromal cells (MSCs). Ortiz et al.  [17], [94] demonstrated that
murine bone marrow-derived MSCs decreased inflammation and collagen deposition in
lung by expression of IL-1R antagonist. Rojas et al. [18] reported that the murine bone
marrow-derived MSCs localized to lung and assumed the phenotypes of lung cells, but
they also suppressed inflammation and triggered production of growth factors. In other
models of acute lung injury, MSCs were shown to suppress proinflammatory cytokines,
edema, and the influx of neutrophils [188], [189]. They improved clearance of bacteria
[190], [191]. The beneficial effects of MSCs were largely explained by the ability of the
cells to modulate immune and inflammatory reactions via several different mechanisms
[25], [48], [192]. Similar beneficial effects of MSCs were also observed in other disease
models, such as sepsis  [193], myocardial infarction [54], [55], [194], and acute kidney
injury [195], [196].
Accordingly,  a  common  theme  in  recent  reports  is  that  MSCs  produce  their
beneficial effects by being activated by signals from injured tissues to express genes that
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modulate  inflammatory  and  immune  responses  [188],  [192].  Among  the  anti-
inflammatory factors MSCs are activated to express is TNF-α stimulated gene/protein-6
(TSG-6)  [54]. TSG-6 was first discovered in the early 1990s and was shown to have
multiple anti-inflammatory effects [85], [197]. It cross-links proinflammatory fragments
of hyaluronan  [198] and catalytically transfers a heavy chain from inter-α-inhibitor to
hyaluronan, thereby inhibiting the cascade of proteases released by inflammation [198],
[199].  It  also  inhibits  transport  of  leukocytes  through  endothelial  cells  [200].
Administration of recombinant TSG-6 was shown to reproduce most of the beneficial
effects of MSCs administration in models of myocardial infarction [54], peritonitis [88],
and corneal injury [87], [91]. Also, Danchuk et al. [86] demonstrated that the beneficial
effects of MSCs in a model of LPS-induced lung injury were partly explained by the
secretion of TSG-6 by MSCs.
Here  we  tested  the  hypothesis  that  beneficial  effects  can  be  produced  by
administration of TSG-6 to target the early inflammatory phase of bleomycin-induced
lung injury. In effect, administration of the protein during the early inflammatory phase
of  the  injury might  be  more  effective  than  administration  of  MSCs.  Therapies  with
MSCs are complex because the cells undergo a lag period of 10–12 h before they are
activated by signals from injured cells to express potentially therapeutic factors such as
TSG-6, and after intravenous (IV) infusion they disappear from the lung after 24 h [54].
We used a rapid and real-time assay for arterial oxygen saturation (SpO2) to follow the
deleterious  effects  of  bleomycin  on  gaseous  exchange  in  the  lung.  The  results
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demonstrated that administration of TSG-6 on 2 and 4 days after bleomycin exposure
decreased  the  initial  cellular  infiltration  into  alveolar  spaces  and  improved  both  the
subsequent decrease in SpO2 levels and the survival of the mice.
V.3 Materials and methods
V.3.1 Animals
Animal use protocol was approved by the Texas A&M  Health Science Center
Institutional Animal Care and Use Committee at Scott and White Hospital. Female 6- to
8-wk-old wild-type (C57BL/6J) mice and female transgenic mice with a  CD44 gene
knockout (B6.Cg-Cd44tm1Hbg/J) obtained from Jackson Laboratories were used for this
study. The mice were kept on a 12-h light-dark cycle and fed and watered ad libitum.
V.3.2 Bleomycin-induced lung injury
Mice were anesthetized with 4% isoflurane in 100% oxygen for 4 min to reach
the level of deep anesthesia and placed on the intubation stand facing upward at a 45° tilt
by using sterile elastic string positioned under the animal’s front incisors. The tongue
was retracted with forceps and the trachea was intubated with a 22-G plastic sterile iv
catheter  (Terumo).  An  external  high-power  light  source  was  used  to  visualize  the
tracheal opening. Bleomycin sulfate from  Streptomyces verticillus  (Sigma-Aldrich) at
2.25 U/kg body wt in 0.9% sodium chloride (Sigma-Aldrich) or 0.9% sodium chloride
alone (sham injury) was instilled through a catheter at volume 4 μl/g body wt in two sets.
The dose per mouse varied from 0.036 to 0.047 U. Mice were kept on the board for an
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additional  90  s  with  the  continued  4%  isoflurane  in  100%  oxygen  anesthesia  via
facemask.
Intravenous  administration  of  recombinant  human  TSG-6 (R&DSystems)  was
performed on days 2 and 4 after bleomycin administration. Mice were anesthetized with
3% isoflurane, the tail vein was visualized by warming the tail, and a 28-G needle was
used to inject rhTSG-6 (50 μg in 50 –150 μl of sterile PBS) or sterile PBS (50 –150 μl).
V.3.3 End point tissue, blood, and bronchoalveolar lavage fluid collection
At  the  indicated  time  points  after  bleomycin  administration,  mice  were
anesthetized  with  3%  isoflurane  in  100%  oxygen  for  3  min  and  euthanized  by
intraperitoneal  injections  of  ketamine-xylazine  solution  at  80  and 8 mg/kg body wt,
respectively. The rib cage was opened without damaging the lungs. Blood was collected
from the  right  heart  ventricle  and  placed in  a  tube  containing  activators  of  clotting
(Terumo  Medical,  Somerset,  NJ)  for  20  min  and  then  stored  on  ice  until  further
processing. Care was used to prevent bleeding into the rib cage. Serum was separated by
centrifuging the tube at 1,500 g for 10 min and stored at 80°C until further analysis.
Immediately following the collection of blood, the trachea was cannulated with a 20-G
plastic IV catheter (Exelint, LosAngeles, CA). Two fractions of BALF were obtained.
The first fraction was obtained by flushing the lungs back and forth fourtimes with a
single volume of 800  μl of PBS containing Halt Protease Inhibitor Cocktail (Thermo
Fisher Scientific, Rockford, IL). The second fraction was obtained by flushing the lung
four additional times each with a volume of 800  μl of PBS without protease inhibitor
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cocktail. The first BALF fraction was centrifuged at 500 g for 10 min at 4°C to obtain a
cell pellet, which was later combined with the cell pellet from the second fraction. The
supernatant was then spun again at 10,000 g for 10 min and stored at 80°C until further
analysis. The cell pellet from the second wash was obtained by centrifugation at 500 g
for 10 min and combined with the cell pellet from the first fraction. To lyse erythrocytes,
the combined pellets were incubated at room temperature with red blood cell lysis buffer
(eBioscience,  San  Diego,  CA)  for  5  min,  centrifuged  at  500  g  for  5  min  at  4°C,
resuspended with 10 ml of ice-cold PBS, and centrifuged again. The supernatant was
discarded and the cells  were then resuspended in PBS containing  1% bovine serum
albumin  (BSA)  (Thermo  Fisher  Scientific),  counted  by  use  of  disposable  Improved
Neubauer Hemocytometers (INCYTO, Cheonan-si, Chungcheongnam-do, South Korea),
and  used  later  for  flow  cytometry  analysis.  After  obtaining  BALF,  the  lungs  were
excised, washed once in ice-cold PBS and immediately frozen and stored in 80°C until
further processing.
V.3.4 Flow cytometry
The  cells  from  BALF  were  prepared  as  described  in  the  previous  section,
counted, resuspended in 100 μl of PBS with 1% BSA, and incubated for 10 min at 4°C
with  anti-CD16/32  antibody  at  a  concentration  0.5  μg  per  1x106 cells  in  100  μl
(eBioscience) to  block nonspecific binding to Fc-receptors.  After  being washed once
with PBS-1% BSA, the cells were incubated for 20 min at room temperature with both
phycoerythrin-Cy7-conjugated  anti-mouse  F4/80  antibody  (eBioscience)  and  FITC-
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conjugated anti-Ly-6G antibody (BD Pharmingen, San Diego, CA). The antibodies were
used at a concentration of 1  μg per 1x106 cells in 100  μl of PBS-1% BSA. Isotype-
matching antibodies at similar concentrations obtained from the same manufacturers and
single-color  labeling  were  used as  controls  for  the specificity of  labeling.  After  two
washes  in  PBS,  the cells  were again resuspended in PBS-1% BSA and analyzed by
FC500 flow cytometer (Beckman Coulter, Brea, CA) to determine macrophage (F4/80-
positive) and neutrophil (Ly-6G-positive) populations.
V.3.5 Cytokine ELISA in BALF and lung tissues
BALF was prepared as described in the previous section and frozen lungs were
homogenized with RIPA buffer (ThermoFisher Scientific). Appropriate dilutions were
used in the assays. Lung protein concentration was determined by using Micro BCA
Protein  Assay  Kit  (ThermoFisher  Scientific)  according  to  the  manufacturer’s
instructions. Cytokine concentrations were determined by using commercially available
ELISA  kits  for  detection  of  IL-6,  TNF-a,  IL-1,  CCL2/MCP-1,  CCL3/MIP-1a,
CXCL2/MIP-2, and CXCL1/KC (R&D Systems,  Minneapolis,  MN) according to the
manufacturer’s instructions.
V.3.6 Histology
Mice  were  anesthetized  with  3% isoflurane  in  100% oxygen  for  3  min  and
euthanized  by  intraperitoneal  injections  of  ketamine-xylazine  solution  as  described
previously.  The  rib  cage  was  opened and the  blood flow was  stopped by placing  a
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permanent silk suture between atria and ventricles of the heart. The trachea was then
cannulated with 20-G IV catheter and the lungs were excised, immediately washed with
PBS, and fixed with 4% paraformaldehyde at pressure 20 cm H2O for 24 h. The lungs
were then dehydrated with graded ethanol solutions and embedded in paraffin.  Five-
micrometer sections were cut with Leitz 1512 microtome (Leitz, Germany) and stained
with a Masson TriChrome Kit (Richard-Allan Scientific, Kalamazoo, MI). The bright-
field images were taken with Nikon Eclipse 80i upright microscope (Nikon, Kawasaki,
Japan), and linear adjustments were made in Adobe Photoshop CS3 (Adobe Systems,
San Jose, CA).
V.3.7 Pulse oximetry
A portable mouse pulse oximeter (STARR Life Sciences) was used to monitor
SpO2 and other physiological  parameters (heart  and breath rates,  pulse distention)  in
free-roaming nonanesthetized mice. The collars of experimental animals were trimmed
of fur at least a day before the beginning of pulse oximetry monitoring. At indicated
experimental time points, mice were anesthetized with 3% isoflurane in 100% oxygen
for 2 min and an extra-small MouseOX collar clip was placed on the animal’s neck.
Mice were allowed to recover from anesthesia (1–2 min) and pulse oximetry readings
were recorded as a Windaq Waveform file at 15-Hz sample rate. After placing the collar
clip,  we  observed  two  sequential  behavioral  states  in  mice:  1)  an  agitated  state,
characterized by frequent movements resulting in an unstable signal, and 2) a relatively
calm state with improved signal  quality.  The measurements were continued to allow
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recording  of  3–5  min  of  stable  signal.  Using  Windaq  Waveform Browser  (DATAQ
Instruments), we extracted data from only the calm state. An in-house Microsoft Excel
(Microsoft) VBAbased script was then used to filter values associated with error-free
signals  implementing  formulas  provided  by the  manufacturer.  With  the  same script,
arithmetic means for each reading were obtained and later used for statistical analysis.
V.3.8 Statistical analysis
Unpaired t-test or one-way ANOVA with Bonferroni’s post hoc analysis was used
to compare two or more groups, respectively. Null hypotheses were rejected at P values
less than 0.05. Survival of animals between groups was compared by log-rank (Mantel-
Cox) test. All statistical analyses were performed with GraphPad Prism software.
V.4 Results
V.4.1  Functional oxygen saturation correlates with changes in cellular infiltrates
and cytokines in BALF
To monitor in real-time the bleomycin-induced injury to the lung, we used a pulse
oximeter to assay SpO2 in mice (Fig. 21A and B). Placing a collar clip on the necks of
the mice agitated them and distorted the reading. However, with care in handling, the
mice became calm so that reliable values with minimum associated errors were readily
obtained. Intratracheal administration of 2.25 U/kg of bleomycin produced a progressive
decrease in SpO2 below 90% reflecting hypoxemia beginning on day 8 (Fig. 21A).
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Figure 21. Pulse oximetry in the bleomycin model of lung injury. A: dynamics of oxygen 
saturation (SpO2) levels in bleomycin-injured and uninjured (sham-injured with NaCl) mice over the 
course of 12 days following injury. Only bleomycin-injured mice dropped SpO2 levels below 90% 
(dashed line) that were significantly lower than in uninjured mice beginning on day 8. B: SpO2 curves
extracted from Windaq files of bleomycin-injured and uninjured mice prior to the beginning of the 
experiment and 12 days after injury. Note visible changes in the SpO2 curve of injured animals 
(bleomycin day 12). C and D: although no significant changes from pre-injury baseline recordings 
(day 0) were detected, heart rates of bleomycin-injured mice were significantly lower on day 12 and 
breath rates were significantly lower on days 4, 6, and 12 compared with uninjured mice. E: weight 
changes normalized to pre-injury (day 0). Significant weight changes were noted on day 6 and 
constituted 20% weight loss in injured mice. P values were calculated between uninjured and ∼
bleomycin-injured groups at each time point by 1-tailed t-test. *P < 0.05, **P < 0.01.
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As expected, the decrease in SpO2 paralleled changes in the BALF. There were
progressive  increases  in  total  cells  and  protein  concentration  (Fig.  22,  A and  D).
Macrophages in the BALF showed an initial decrease and then increased on day 6 and
day 12 (Fig. 22B). Neutrophils were more variable but showed increases vs. a control in
the number of neutrophils from days 2  to  12 (Fig. 22C). As also expected, the major
changes in cytokine and chemokine levels occurred earlier than the decrease in SpO2
(Fig. 23). Levels of the proinflammatory cytokines IL-6 and TNF-α in the BALF were
increased on  day 2 and then decreased. Similarly, the chemokines CCL2 and CXCL1
were increased on day 2 and then decreased.
In addition, the decrease in SpO2 roughly paralleled a decrease in body weight
(Fig. 21E) and pathological changes in lung morphology (Fig. 22E). There were more
variable decreases in heart rate and respiration rate (Fig. 21, C and D).
V.4.2 Intravenous administration of TSG-6 improved functional oxygen saturation
and survival of bleomycin-injured mice
We elected to test the potential effectiveness of TSG-6 in suppressing the early
inflammatory  phase  in  the  bleomycin  model.  Day  8  post  injury  was  chosen  for
performing last end point assays in further experiments. This was based on the findings
from the optimization of the bleomycin model (Fig.  21-23) in which SpO2 levels  in
bleomycin-injured mice were significantly different from uninjured mice  on day 8  and
the extent of inflammation paralleled SpO2 levels. Additionally, the bleomycin-injured
mice were observed until day 21 for long-term survival.
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Figure 22. Temporal changes in cell composition of bronchoalveolar lavage fluid (BALF) and
histological changes in the lungs following bleomycin injury. BALF was collected at 2, 4, 6, and
12 days following bleomycin injury and at 12 days from uninjured mice (A–D); for histology, lungs
were collected at day 8 (E). A and D: total number of cells in BALF was counted with a disposable
hemocytometer. Protein concentration (Conc) in BALF was determined by the BCA assay. Both total
BALF cell number and protein concentration increased temporally. Both parameters were the highest
by  day  12  postinjury  and  were  significantly  higher  than  in  the  uninjured  controls.  Significant
differences in total cells and protein concentration between groups were also observed at various time
points as indicated in the figure. B and C: the cells were labeled with antibodies against macrophage
(F4/80)  and  neutrophil  (Ly6G)  markers  and  analyzed  by  flow  cytometry.  Macrophages  and
neutrophils  also  increased  temporally  following  bleomycin  injury.  However,  on  days  2  and  4,
whereas  total  cells  and  macrophages  were  either  similar  to  or  lesser  in  number  compared  with
uninjured  mice,  neutrophil  numbers  on  those  days  were  higher  than  the  uninjured  mice.  E:
representative  images  of  Masson's  trichrome-stained  lung  sections  from  bleomycin-injured  and
uninjured mice from day 8. Lower row represents magnification of area inside orange frame in upper
row.  Area  of  inflammation  and fibrosis  is  clearly visible  in  bleomycin-injured  lungs.  Values  are
represented as arithmetic means ± SE (n = 3 mice per group). P values were calculated by 1-way
ANOVA with  a  post  hoc  Bonferroni's  multiple  comparison  analysis  performed  between  all  the
groups. *P < 0.05, **P < 0.01, and ***P < 0.001.
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Figure 23. Temporal changes in cytokine expression of BALF in the bleomycin model of lung 
injury. Cytokine expression levels on days 2, 4, 6, and 12 were assayed in BALF by use of ELISA. 
IL-6 (A), TNF-α (B), CCL2/MCP-1 (C), and CXCL1/KC (D) expression levels were the highest on 
day 2 and were significantly higher than those in uninjured mice. Expression levels of all the 
cytokines tested returned to close to uninjured levels by days 6 and 12. Significant differences in 
cytokine levels between groups on the individual days tested are indicated. Values are represented as 
arithmetic means ± SE (n = 3 mice per group). P values were calculated by 1-way ANOVA with a 
post hoc Bonferroni's multiple comparison analysis performed between all the groups. *P < 0.05, **P
< 0.01, and ***P < 0.001.
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A high (50 μg) and a low dose (12.5 μg) of TSG-6 were tested to determine the
most effective dose.  The functional SpO2 data  on  day 8 (Fig.  24,  A and B) and the
cellular infiltrates on day 5 (Fig. 24, C-H) suggested that the high 50 μg dose would be
most beneficial in reducing early inflammation and improving function in the bleomycin
lung injury model. Hence the high dose (50 μg) was used for the rest of the study. The
TSG-6 protein (50 μg) was infused intravenously on day 2 and day 4 to target the early
inflammatory stage. As expected, there was a decrease in early signs of inflammation by
a decrease in total cells, macrophages, and neutrophils in BALF on  day 5 (Fig. 25).
There was also a decrease in the proinflammatory cytokines TNF-α on day 2 and IL-6 on
day 3 (Fig. 26, A and B). However, IL-1β expression in lung tissues was increased in
TSG-6-treated mice on day 2 (Fig. 26C). In addition, administration of TSG-6 increased
the BALF levels of the chemokines CCL2, CCL3, CXCL1, and CXCL2 on day 2 (Fig.
26, D-G). Protein concentration levels were not significantly different between TSG-6-
and PBS-treated mice (Fig. 26H) at all examined end points. 
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Figure 24. TNF-α-stimulated gene/protein 6 (TSG-6) dose response on SpO2 and cellular 
infiltrates. A: effect of TSG-6 dose response on the dynamics of SpO2 levels over the course of 8 
days following bleomycin (Bleo) injury. A high dose (50 μg) and a low dose (12.5 μg) were 
administered on days 2 and 4 following bleomycin injury. B: dot plot represents the distribution of 
SpO2 levels on day 8. Significant differences between high dose of TSG-6 and PBS groups was 
observed on day 8. For the analysis of cellular infiltrates, BALF was collected on days 2, 3, 5, and 8 
following bleomycin injury. From day 3 onward following injury of the lungs with bleomycin, total 
cells (C) and macrophages (D) in BALF increased in the low-dose TSG-6 mice compared with PBS 
control mice. F and G: the high dose of TSG-6 lowered these parameters compared with PBS-treated 
mice with statistically significant differences between these 2 groups observed only on day 5. E and 
H: the low dose of TSG-6 increased neutrophil numbers early on day 2, whereas the high dose of 
TSG-6 maintained the neutrophil infiltration lower than PBS mice at all time points. Values are 
represented as arithmetic means ± SE (n = 5–8 mice per group). For the SpO2 data, P value was 
calculated between PBS and TSG-6 groups by 1-tailed t-test. For the cellular infiltrates data, P values 
were calculated by 1-way ANOVA with a post hoc Bonferroni's multiple comparison analysis 
performed between all the groups. *P < 0.05, **P < 0.01.
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Figure 25. TSG-6 treatment reduces cellular infiltration in the lungs during the early 
inflammatory phase. BALF was collected at 12 h and on days 2, 3, 4, 5, and 8 following bleomycin 
injury. On days 2 and 4 alone, BALF was collected 4 h after TSG-6 (50 μg) administration. From day
4 onward following injury of the lungs with bleomycin, total cells (A), macrophages (B), and 
neutrophils (C) in BALF increased compared with uninjured mice. TSG-6 treatment lowered these 
parameters compared with PBS-treated mice with statistically significant differences between these 2 
groups observed only on day 5. Insets represent changes on day 5 in individual mice from the 3 
groups. Note that on days 2 and 3 following bleomycin injury, macrophages (B) were significantly 
lower in PBS and TSG-6 groups (√√ = P < 0.01, √√√ = P < 0.001) compared with uninjured mice. 
Values are represented as arithmetic means ± SE (n = 5–8 mice per group). P values were calculated 
by 1-way ANOVA with a post hoc Bonferroni's multiple comparison analysis performed between all 
the groups. P values represented in the larger panels only indicate significant differences between 
PBS and TSG-6 groups following bleomycin injury. P values represented in the insets indicate 
significant differences between all 3 groups. *P < 0.05 and **P < 0.01.
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Figure 26. Temporal changes in cytokine/chemokine expression following TSG-6 treatment in 
the bleomycin model of lung injury. TSG-6 (50 μg) treatment significantly decreased TNF-α (A) 
expression on both days 2 and 3, whereas decreasing IL-6 (B) only on day 3 in comparison with PBS-
treated mice. Surprisingly, TSG-6 initially increased IL-1β (C) expression on day 2 but decreased it 
significantly by day 8. TSG-6 treatment significantly increased expression of CCL2/MCP-1 (D), 
CCL3/MIP-1α (E), and CXCL2/MIP-2 (G) chemokines on day 2, whereas significantly increasing 
CXCL1/KC (F) on both days 2 and 4. No significant differences in protein concentration (H) were 
observed after TSG-6 treatment. Values are represented as arithmetic means ± SE (n = 5–8 mice per 
group). P values were calculated by 1-way ANOVA with a post hoc Bonferroni's multiple comparison
analysis performed between all the groups. Only significant differences between bleomycin-injured 
(PBS and TSG-6) groups are indicated in the figure: *P < 0.05, **P < 0.01, and ***P < 0.001.
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These  changes  were  accompanied  by an  improvement  in  both  the  SpO2 and
survival  of  the  bleomycin  injured mice (Fig.  27A and B).  Furthermore,  there was a
significant improvement in percent change of initial weight on days 7 and 8 following
TSG-6 treatment  (Fig.  27E),  whereas there were no significant  changes in heart  and
breath  rates  between  groups  (Fig.  27C  and  D).  However,  there  was  no  significant
reduction in fibrosis in TSG-6-treated lungs as measured by hydroxyproline content in
the lungs on day 8 (data not shown), suggesting that there was no increase in fibrosis at
this time.
V.4.4 The effects of TSG-6 are not observed in mice that do not express CD44
Previous reports demonstrated that some of the anti-inflammatory effects of TSG-
6 involved its interaction with CD44 either by directly binding to the receptor or in a
complex with hyaluronan (7, 24, 51). Therefore we elected to test the hypothesis that the
beneficial effects of TSG-6 observed in the bleomycin model would not be observed in
transgenic mice that did not express CD44 (42). As expected, TSG-6 administration had
no effect in bleomycin-treated mice on SpO2 (Fig. 28, A and B), or on BALF content of
total cells, macrophages or neutrophils (Fig. 28, C–E). Also, administration of TSG-6
had no effect on the BALF levels of the cytokines IL-6, TNF-α, and IL-1β (Fig. 29, A–
C).  Similarly it  had no effect  on the BALF levels of the chemokines CCL2, CCL3,
CXCL1, or CXCL2 (Fig. 29, D–G) and protein concentration (Fig. 29H).
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Figure 27. TSG-6 improves functional SpO2 and survival following bleomycin injury. A: effect 
of TSG-6 (50 μg) treatment on the dynamics of SpO2 levels over the course of 8 days following 
bleomycin injury (representative of 3 independent experiments). Significant differences between 
TSG-6 and PBS groups were observed on days 5, 6, and 8. Note that TSG-6 treatment prevented the 
drop of SpO2 levels below 90% threshold (dashed line) through day 8. P values represented in panel 
(A) only indicate significant differences between PBS and TSG-6 groups following bleomycin injury.
B: Kaplan-Meier curves depicting survival proportions after administration of bleomycin. TSG-6 
administration significantly improved survival compared with PBS-treated mice [P = 0.0363, log-
rank (Mantel-Cox) test]. Dynamics of heart rate (C) and breath rate (D) following bleomycin injury 
and TSG-6 administration. No significant changes from preinjury baseline recordings (day 0) were 
detected. E: weight changes normalized to preinjury (day 0). Significant weight changes between 
bleomycin-injured (PBS and TSG-6) groups was noted on days 5, 7, and 8 and constituted 20% ∼
weight loss in injured mice. Values are represented as arithmetic means ± SE (n = 5–8 mice per 
group). P values were calculated by 1-way ANOVA with a post hoc Bonferroni's multiple comparison
analysis performed between all the groups. *P < 0.05 and **P < 0.01.
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Figure 28. CD44 partly mediates beneficial effect of TSG-6 in vivo. A: effect of TSG-6 (50 μg) 
treatment on the dynamics of SpO2 levels over the course of 8 days following bleomycin injury 
(representative of 2 independent experiments) in CD44 knockout mice. No significant differences 
between TSG-6 and PBS groups were observed on any of the days tested. Note that SpO2 levels of 
both TSG-6 and PBS groups remained slightly above 90% threshold (dashed line) through day 8. B: 
dot plot represents the distribution of SpO2 levels on day 8 following bleomycin injury. Significant 
differences were observed between bleomycin-injured and uninjured mice, although, in the absence 
of CD44, TSG-6 failed to improve SpO2 levels over the PBS-treated group. C–E: BALF was 
collected in a similar manner as described above for the wild-type mice. No significant differences 
were observed between total cells, macrophages, and neutrophil numbers between TSG-6 and PBS-
treated groups. Values are represented as arithmetic means ± SE (n = 5–8 mice per group). P values 
were calculated by 1-way ANOVA with a post hoc Bonferroni's multiple comparison analysis 
performed between all the groups. *P < 0.05.
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Figure 29. Temporal changes in cytokine/chemokine expression following TSG-6 treatment in 
CD44 knockout mice. No significant changes were observed in CD44 knockout mice after TSG-6 
(50 μg) treatment in any of the proinflammatory cytokines examined such as IL-6 (A), TNF-α (B), 
and IL-1β (C), or in the expression of chemokines such as CCL2/MCP-1 (D), CCL3/MIP-1α (E), and
CXCL2/MIP-2 (G), or in protein concentration (H) levels. However, TSG-6 treatment significantly 
decreased CXCL1/KC (F) levels only on day 5 compared with the PBS group. Values are represented
as arithmetic means ± SE (n = 5–8 mice per group). P values were calculated by 1-way ANOVA with 
a post hoc Bonferroni's multiple comparison analysis performed between all the groups. No P values 
are indicated on this figure since there were no statistical differences between the bleomycin-injured 
(PBS and TSG-6) groups in most of the cytokines/chemokines tested and at any of the time points 
examined.
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V.5 Discussion
The  assay  of  SpO2 with  pulse  oximeter  provided  a  useful  measure  of  the
deleterious effects of bleomycin on the lungs of mice. The data are obtained in a rapid,
quantitative, and real-time manner without the need to euthanize the mice. Therefore this
assay has many advantages both in following the natural progression of the injury and
for testing potential therapies for lung injury.
The response of the lung to injury by bleomycin is complex and occurs in several
relatively distinct phases  [181]–[185]. The beneficial effects previously observed with
administration of MSCs may in fact reflect the plasticity of the cells in responding to
injured tissues in a manner that is appropriate to the type and phase of the injuries [17],
[94]. For example, MSCs were shown to produce beneficial effects  [25], [48], [189],
[192], [201] in various injury models by expressing factors that enhance vascularization
(VEGF  and  IL-6),  enhance  cell  proliferation  (TGF-β,  KGF),  modulate  immune
responses  (indoleamine  2,3-dioxygenase  in  human  MSCs,  iNOS with  mouse  MSCs,
CCL2, MMP-9), reduce reactive oxygen species and apoptosis (stanniocalcin-1), and are
antibacterial (peptide LL-37).
The characterization of the bleomycin model gave us an exact timeline of cellular
and morphological events that occurred after the injury. Hence it allowed us to target
specific  inflammatory and functional events to examine whether TSG-6 had positive
effects  on reducing cytokine storm and infiltration of  inflammatory cells  and finally
whether  these  early  reductions  translated  to  functional  improvement  and  improved
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survival. In the experiments described here, we elected to use iv administration of TSG-6
over intratracheal administration for several reasons: 1) clinical relevance, 2) increased
risk of physical insult resulting from the repeated intubation required, and 3) oxygen-
exacerbated  damage  to  the  lung  during  anesthesia  [183],  [202]–[204].  Under  the
conditions  employed  in  this  study,  we reached  therapeutic  effect  in  the  lungs  by iv
infusion of 50 μg TSG-6 protein. This was demonstrated by an improvement in oxygen
saturation, increased survival, and modulation of cytokines following bleomycin injury.
To test TSG-6 in the bleomycin model, we infused the protein during the early
inflammatory  phase  marked  by  the  appearance  of  neutrophils  and  proinflammatory
cytokines (IL-6 and TNF-α) in the BALF (day 2 and day 4). The TSG-6 decreased the
inflammatory  phase  as  indicated  by  a  decrease  in  BALF  on  day  5  of  total  cells,
macrophages, and neutrophils. It  also decreased proinflammatory cytokine TNF-α on
day 2, and IL-6 on day 3. At the same time, administration of TSG-6 increased the levels
in BALF of chemokines (CCL2/MCP-1, CCL3/MIP-1α, CXCL1/KC, and CXCL2/MIP-
2) that attract macrophages to resolve inflammation. The potential beneficial effects of
the increase in chemokines is consistent with the observations by Liang et al. [205] that
mice  with  lung-specific  overexpression  of  CCL2/MCP-1  were  protected  from
bleomycin-induced  lung  injury because  of  increased  recruitment  of  cells  capable  of
clearing apoptotic cells.
However, our data on day 5 demonstrate that the early increases in MCP-1 after
TSG-6 administration only translated to a modest increase in macrophage recruitment
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between days 2 and 5 but that these increases were still  significantly lower than the
number of macrophages recruited in the PBS-treated group. To explain this discrepancy,
we speculate here that the macrophages recruited to alveolar spaces in TSG-6-treated
animals possibly contained a larger proportion of alternatively activated or regulatory
M2 macrophages. This could result in decrease of inflammation and subsequent decrease
in the recruitment of proinflammatory monocytes from the circulation. In support of this
theory, Roca et al. [206] have demonstrated that CCL2 (MCP-1) in the lungs can induce
M2-type macrophage polarization. Furthermore, employing models of gastric aspiration
and lung contusion, there is evidence for the protective effect of CCL2 and its receptor
CCR2 in the pathogenesis of acute lung injury (ALI) by attenuating the inflammatory
response,  decreasing  neutrophil  infiltration,  increasing  macrophage  recruitment,
activation of the M2 polarized macrophages, and improved survival  [187], [207]. In a
pneumonia model of ALI, Amano et al. [208] also demonstrated that CCL2 was critical
in  decreasing  neutrophil  infiltration  and  increasing  the  phagocytosis  of  apoptotic
neutrophils by alveolar macrophages. Thus this study might also help explain why there
was decreased neutrophil recruitment on day 5 in our model following TSG-6 treatment
despite elevated levels of MIP-2 and KC chemokines on day 2. We speculate that TSG-6
treatment  of mice that  were injured with bleomycin results  in  a  complex interaction
between different types of cells and their corresponding cytokines, which needs further
investigation. However, the combined results from these studies lead us to conclude that
the  early  elevated  chemokine  levels  following  TSG-6  treatment  in  our  model  could
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partly  explain  the  overall  beneficial  effects  that  we  observed  such  as  resolution  of
inflammation  and  reduced  neutrophil  numbers  due  to  either  reduced  recruitment  of
neutrophils or their increased phagocytosis, thus resulting in improved oxygenation and
survival.  In  addition,  decrease  in  levels  of  TNF-α by TSG-6 could  have  resulted  in
decreased levels of apoptosis in alveolar epithelium as indicated by Wang et al.  [209],
although apoptosis was not addressed in our study. Thus the cumulative effects of TSG-6
on the early inflammatory stage in part explained the subsequent increase in SpO2  and
survival seen in treated mice compared with controls (Fig. 30). However, in this model,
there was some mortality in bleomycin-injured mice treated with PBS, with the earliest
occurrence beginning on day 6. Thus, had these mice survived to day 8, the average
SpO2 levels  would  have  been  much  lower  and  accordingly  the  numbers  of  cellular
infiltrates in BALF would have been much higher compared with the bleomycin/TSG-6
group than what is  represented.  Although not explored here,  more frequent or larger
doses on TSG-6 may have been even more effective.
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Figure 30. Modulatory effects of TSG-6 in bleomycin-injured lungs. The beneficial effects of 
TSG-6 on modulating the early inflammatory phase in bleomycin-injured lungs is indicated by 1) a 
decrease in proinflammatory cytokines IL-6 and TNF-α (days 2 and 3), 2) an increase in chemokines 
CCL2, CCL3, KC, and CXCL2 (days 2 and 4), and 3) a corresponding decrease in total cells and 
infiltrating cells such as macrophages and neutrophils (day 5). These early modulatory events 
promoted by TSG-6 lead to functional improvement by preventing the drop of SpO2 levels below 
90% (day 8) and decreased mortality (weeks 1-3).
TSG-6 has been previously shown to have multiple interactions that can be anti-
inflammatory  [85],  [197], [198],  [200].  Particularly,  in a recently published study by
Choi et al. [88], it was shown that at least part of the inflammatory action of TSG-6 in
the peritonitis model could be explained by its direct or indirect interaction with CD44
on resident macrophages. TSG-6 bound to CD44, either directly or in a complex with
hyaluronan,  to  dissociate  CD44  from  TLR2  and  thereby  limit  TLR2-driven  NF-κB
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signaling.  In  CD44 knockout  mice,  bleomycin  induced  an  unrelenting  inflammatory
response  in  a  TLR2-  and  TLR4-dependent  manner  [210],  [211].  TSG-6  was  also
effective in wild-type mice but ineffective in CD44 knockout mice employed in a mouse
model for sterile injury to the cornea [212]. In the present study, we employed the CD44
knockout mouse model, similar to that used in the study by Choi et al. In these mice,
CD44 expression is constitutively knocked out in all cell lineages and not restricted to
only  macrophages.  Also,  on  the  basis  of  previous  publications  [87],  [88] we
hypothesized that  resident  macrophages  with functional  CD44 could be important  in
mediating  the  effects  of  TSG-6  in  bleomycin-injured  lungs.  Since  TSG-6  was  not
effective  in  reducing  inflammation  and  improving  bleomycin-induced  injury  in  the
CD44  knockout  mice,  the  results  were  consistent  with  the  conclusion  that  TSG-6
decreased inflammation by interacting with functional CD44 on resident macrophages in
a manner  previously demonstrated in  zymosan-induced peritonitis  [88] and chemical
injury to the cornea [87].
Toxic agents such as bleomycin trigger a cascade of destructive events in the
lung. It seems unlikely that any single therapy can halt all of them. The results presented
in this study demonstrate that the systemic administration of TSG-6 improved functional
outcome and survival of bleomycin-injured mice by modulating inflammation at early
stages. Hence these data suggest that it may be useful to target specific phases in the
cascade with agents such as TSG-6 for the early inflammatory phase. Similar phase-
specific strategies may be useful for other diseases of the lung.
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CHAPTER VI
CONCLUSIONS
Mesenchymal stem cells represent an attractive therapeutic option based on the
results from preclinical studies. Most of beneficial effects of MSCs, such as modulation
of immunity, tissue regeneration, inhibition of inflammation is attributed to their ability
to actively respond to the surroundings and produce therapeutic factors [48], [62]. There
is a need to investigate both, basic MSCs biology, and their therapeutic potential.
The dissertation focused on studying basic  biology of MSCs in vitro and the
effects of the cells and their secreted factor TSG-6 in vivo models of diseases.
VI.1 In vitro biology of single-cell-derived MSCs colony
In  vitro  single-cell  colony  formation  was  chosen  as  an  object  to  study  the
heterogeneity of MSCs in culture. It was hypothesized previously that different parts of
the colony exhibit different microenvironments that might affect their fate [33]. We used
laser-capture microdissection to specifically isolate two distinct parts of MSCs colony –
densely packed inside (IN) and outside (OUT). Using comparative microarray analysis
we showed that OUT cells expressed many cell-cycle, division and motility genes, while
IN  cells  expresses  ECM-related  genes.  These  findings  were  also  confirmed  by
immunofluorescence of different parts of the colonies. Not surprisingly we found that IN
region of the colonies differentiated into fat and bone more readily than OUT region.
However the functional assays did not produce expected results. We sub-cloned IN and
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OUT regions and showed virtually no difference in growth and clonogenicity of the cells
regardless of the origin. This result suggests that in vitro colony of MSCs represents a
unique niche-like structure that contains distinct microenviroments but able to preserve
the characteristics of cells, such as ability to differentiate and self renew.
VI.2 In vivo effects of MSCs
We chose mouse model of HCl-induced lung injury to test the effects of MSCs.
The chosen model mimics one of the leading causes of deaths in ICU patients – acute
respiratory distress syndrome. We utilized two treatment approaches – administration of
MSCs intravenously and intraperitoneally. To our surprise, intravenous injection of the
cells  did  not  produce  beneficial  results.  On  the  contrary,  there  was  an  increase  in
inflammatory cell in the bronchial lavage fluid after intravenous MSCs administration.
Intraperitoneal injections, however, improved lung function and reduced inflammation in
the lungs. Intraperitoneal administration of MSCs has been shown beneficial in several
models of diseases  [86], [91], [95], [99], moreover, intraperitoneal administration was
shown to be superior to intravenous in certain models [95]. The negative effect of MSCs
after intravenous administration could be attributed to several factors, including the lung
embolization  [54],  [55],  donor  variation  [37]–[39] and  the  model  itself.  Further
investigation is needed to address these issues.
Little is known about the fate of MSCs after the administration inside peritoneal
cavity. We followed the fate of human MSCs administered i.p. using several methods. As
we reported previously [65] we also observed the aggregation of MSCs within minutes
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after  the  injection.  When  the  aggregates  of  MSCs  were  analyzed  by
immunofluorescence,  we discovered the presence of CD11b and B220 positive cells,
possibly  B1  cells  and  peritoneal  macrophages.  The  aggregates  of  MSCs  were  free-
floating or adhered to various tissues in peritoneal cavity. Particularly we showed the
preferential adherence of the aggregates to mouse omentum. Very few MSCs were found
in mesentery, lymph nodes and spleen. The omentum has gained attention in scientific
literature  recently.  Thus,  it  was  shown that  it  contains  clusters  of  immune cells  that
include macrophages and B-cells [213]–[215]. These clusters participate in mounting the
immune  response  to  viruses  [164] and  also  respond  to  pathogens  such  as  LPS.
Importantly omental milky spots participate in transport of lymphocytes from and into
systemic  circulation  and  serve  as  site  of  migration  and  adherence  for  cancer  cells
originating in peritoneal cavity [165], [215], [216].
Aggregated and adhered MSCs survived for less than a week and recruited the
cells to omentum and peritoneal cavity. The aggregation and recruitment of immune cell
pre-conditioned the immune system in peritoneal cavity.  Analysis of cytokines inside
peritoneal cavity showed mixed response with early peak of type-1 related cytokines
(IL12p70,  TNF-α)  and prolonged peaks  of  type-2  cytokines  (IL13,  PGE2).  Systemic
administration  of  LPS  unexpectedly  resulted  in  increase  of  production  of  pro-
inflammatory cytokines.
The responses of naive mice to MSCs could be attributed to interaction of human
cells with mouse immune cells or reactivity of host to the antigens from bovine serum
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used to culture the cells and carried by MSCs [170]. In addition to conventional immune
cells,  peritoneal  cavity contains special  class  of recently discovered innate  lymphoid
cells [159]–[161]. Their characteristics is lack of T- or B-cell markers and the ability to
produce type-2-associated cytokines earlier than canonical Th2 cells [217]. Interestingly
we showed early cytokine production, including Th2-related cytokines IL13, PGE2 in
response to MSCs. It will be important to investigate in future studies whether MSCs
communicate with these cells in peirtoneal cavity or elsewhere in a body.
VI.3 In vivo effects of TSG-6
To study the  effects  of  TSG-6 in  models  of  lung injury we administered  the
protein  intravenously  in  HCl-injured  and  bleomycin-injured  mice.  While  TSG-6
treatment  of  bleomycin-injured  mice  prevented  functional  decline,  there  was  no
significant effect of TSG-6 on lung function in HCl-induced lung injury. In both models
TSG-6 was effective in diminishing the inflammation in the lungs, in support of previous
studies in lung injury  [86] and other models [54], [87], [175]. As proposed by Choi et al,
TSG-6 could inhibit inflammatory pathways in macrophages by acting through CD44
receptor and preventing TLR-2-induced NFkB translocation [88]. Similarly we showed
that  CD44 knockout  mice  failed  to  respond  to  TSG-6  treatment.  Future  studies  are
necessary to determine the effectiveness of TSG-6 in other models of lung injury and in
clinical settings.
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APPENDIX A
SUPPLEMENTARY INFORMATION FOR CHAPTER II
Figure A-1. Quality of extracted RNA from laser-capture microdissection samples.
151
Figure A-2. Subcloning of IN and OUT cells. Representative colonies from the subcloning 
experiment at passage 2 and 6 for donor 5064. Both the IN and OUT regions generated similar 
colonies. Scale bar: 1 mm. Abbreviations: IN, inner region of a colony; OUT, outer region of a 
colony; P, passage.
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Figure A-3. Density analysis of type I and II colonies. Representative colonies from donor 7012 
analyzed by staining with crystal violet and densitometry. Scale: 0-255 (black- white).
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Table A-1. Genes significantly up-regulated in inside (IN) of the colony when compared to the 
outside (OUT) of the colony. 
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Table A-1 (continued)
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Table A-1 (continued)
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Table A-2. Genes significantly up-regulated in outside (OUT) of the colony when compared to 
the inside (IN) of the colony.
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Table A-2 (continued)
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APPENDIX B
SUPPLEMENTARY INFORMATION FOR CHAPTER IV
Figure B-1 Detection of MSCs in mouse tissues and peritoneal lavage by real-time PCR. (A) 
Standard curves of known amounts of human cells added to mouse tissues plotted versus 
corresponding delta Ct values (Ct human GAPDH - Ct values eukaryotic 18S) obtained by real-time 
PCR in the same tissues. Points represent average values for delta-Ct, lines represent logarithmic 
model fit. (B) Peritoneal lavage from human MSCs-injected BALB/c was collected and total number 
of recovered cells was enumerated with hemocytometer. Values are mean +/- SEM, n= 4-5. 
Abbreviations: OM – omentum, MT – mesentery, PLP – cell pellet from peritoneal lavage, JLN - 
jejunal lymph nodes, SP – spleen.
Figure B-2. Effects of IP injected MSCs to cytokine levels in the mouse serum. Mouse IL10 and 
IL13 levels in the serum were assayed 72 hours after IP injection of MSCs.
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Figure B-3. Effect of MSCs dose and bone marrow donor to cytokine production in the 
peritoneum. Mouse IL10, IL13 and PGE2 were assayed at 72 hours after IP MSCs or HBSS (Ctrl) 
administration into BALB/c mice. (A) Mouse cytokine production in the peritoneum in response to 3 
donors. (B) Peritoneal levels of mouse cytokines after administration of various doses of MSCs. *, 
p<0.05; **, p<0.01; ***, p<0.001 compared to controls.
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Table B-1. Characteristics of the MSCs donor samples used in the current study. Donors identified by anonymous number and sampling of marrow from 
left (L) or right (R) iliac crest/gender/age were assayed in vitro for growth, clonogenicity, osteogenic and adipogenic differentiation and epitope markers in vitro. 
Donora
(ID#/gender
/age)
P0
Yieldb
(x 106)/
days
P0→P1 Yield
(Master
Bank)c
(plating cells
per cm2 /
harvest cells
per cm2 /days)
P1
Cumulative
PDsd
P1→P2 Yield
(Working Bank)
(plating cells per
cm2 /harvest cells
per cm2 /days)
P2
Cumulat
ive PDs
P2 Diff. e
(osteo/
adipo/
CFU)
P2 Epitopesf
(+/-)
7032R/M/26 0.8/6 50/14557/8 j+8.3 50/6000/6 j+6.8 3/3/49 >95/<3
7068L/M/37 1.17/5 50/7595/8 j+7.2 100/7546/7 j+13.4 3/4/45 >95/<3
7075L/M/24 2.96/6 100/6329/7 j+6.0 100/9287/7 j+12.5 4/1/49 >95/<3
aDonors identified by anonymous number and sampling of marrow from left (L) or right (R) iliac crest/gender/age.
bP0 yield defined as number of cells obtained by plating mononuclear cells from ficoll gradient at high density (6,000 to 30,000 per cm2)/ days cells were 
incubated.
cMaster Bank (P1 cells) defined by number of cells plated per cm2/number of cells harvested per cm2/days of incubation.
dCumulative population doublings (PD) defined as j + observed value because number of population doublings required to generate P0 cells cannot be estimated.
PD calculated as 2n = fold-increase or n = log10 [fold-increase]/0.301.
eP2 Diff. assayed by culture of aliquots in differentiation conditions and visually scoring on +1 to +4 scale after staining with Alizarin Red or Oil-Red-O. Coony 
forming units (CFUs) assayed by plating at very low density to obtain % cells that generate colonies in 2 weeks.
fPositive epitopes (CD-29, -44, -49c, -59, -90, -105, -147 and -166) and negative epitopes (CD-34, -36, -45, and -117)
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Table B-2. Goodness of logarithmic fit of standard curves. Real-time PCR for human GAPDH and eukaryotic 18S was performed on RNA obtained from a 
mixture of mouse tissues and human MSCs. Standard curves were built and non-linear (logarithmic) regression model was fit into the data (Fig. III.1A). The 
table shows the goodness of fit (r2) and formula used to derive MSCs number in the tissues.
Tissue r2 Formula
JLN 0.96 f(x)=-0.88ln(x)+25.20
SP 0.97 f(x)=-1.24ln(x)+29.97
PLP 0.96 f(x)=-0.93ln(x)+24.37
MT 0.96 f(x)=-0.98ln(x)+27.25
OM 0.99 f(x)=-1.21ln(x)+29.11
Abbreviations: OM – omentum, MT – mesentery, PLP – cell pellet from peritoneal lavage, JLN - jejunal lymph nodes, SP – spleen.
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Table B-3. Biological replicates of Ct values for eukariotic 18S and human GAPDH assayed by real-time PCR in mouse tissues after MSCs 
administration. Individual Ct values for human GAPDH and eukaryotic 18S related to Figs. III.1C, B-1A and B-1B.
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